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Based on: 
Angiotensin II type 2 receptor-mediated vasodilation. Focus on bradykinin, NO 
and endothelium-derived hyperpolarizing factor(s).  
Vascular Pharmacology 2005, 42:109-118. 
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Summary 
 
Angiotensin (Ang) II type 1 (AT1) receptors account for the majority of the 
cardiovascular effects of Ang II, including vasoconstriction and growth stimulation. 
Recent evidence, mainly obtained in animals, suggests that Ang II type 2 (AT2) receptors 
counteract some or all of these effects. This review summarizes the current knowledge on 
the vasodilator effects induced by AT2 receptors in humans and animals, focussing not 
only on the mediators of this effect, but also on the modulatory role of age, gender, and 
endothelial function. It is concluded that AT2 receptor-mediated vasodilation most likely 
depends on the bradykinin – bradykinin type 2 (B2) receptor – NO – cGMP pathway, 
although evidence for a direct link between AT2 and B2 receptors is currently lacking. If 
indeed B2 receptors are involved, this would imply that, in addition to NO, also the wide 
range of non-NO ‘endothelium-derived hyperpolarizing factors’ (EDHFs) that are 
released following B2 receptor activation (e.g., K+, cytochrome P450 products from 
arachidonic acid, H2O2 and S-nitrososothiols), could contribute to AT2 receptor-induced 
vasodilation.  
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Introduction 
 
The octapeptide angiotensin (Ang) II mediates its biological actions by activating 
multiple intracellular pathways following its binding to membrane-bound receptors. Two 
Ang receptor subtypes are present in humans: Ang II type 1 (AT1) and type 2 (AT2) 
receptors.1-3 Most of the known cardiovascular effects induced by Ang II (e.g., 
vasoconstriction, water and salt retention, aldosterone synthesis and release, growth and 
remodelling) are mediated via AT1 receptors. Recent studies emphasize the importance of 
the AT2 receptor in the cardiovascular system.4-10 AT2 receptor-mediated effects will 
become apparent especially during AT1 receptor blockade, because the increased Ang II 
levels that accompany such blockade will predominantly result in AT2 receptor 
stimulation. It has even been suggested that this mechanism underlies the beneficial 
effects of AT1 receptor blockade.11,12  
 
AT2 receptors and vasodilation: results from animal studies 
In vitro experiments in cultured cells and isolated vessels, as well as in vivo studies in 
rats and mice, including studies in transgenic animals, have shown that AT2 receptor 
stimulation counteracts some or all of the above-mentioned effects mediated via AT1 
receptors.4,13-21 The vasodilator effects have been investigated most intensely,4,22-26 
although not all studies agree on this matter.27,28  
AT2 receptors are highly expressed during fetal development,2,29,30 and re-appear in large 
numbers under pathological conditions.26,31 This does not mean that AT2 receptor are 
absent in healthy adult animals. In fact, AT2 receptor-induced vasodilation can be 
observed in normal adult animals.4,32,33  
AT2 receptors are G-protein-coupled receptors,32 and their stimulation results in the 
activation of protein phosphatases,34 thereby directly reversing the effects mediated by 
protein kinases in response to AT1 receptor stimulation. Alternatively, as AT1 and AT2 
receptors also form heterodimers,35 AT2 receptor-mediated effects may occur through a 
direct interaction with AT1 receptors, possibly even in a ligand-independent manner.36  
Many studies support a link between AT2 receptor stimulation and the NO-cGMP 
pathway, either directly or via bradykinin and subsequent B2 receptor activation.4,18,22,33,37-39 
Chapter 1 
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In support of a role for NO, the AT2 receptor-mediated vasodilator effects of Ang II in the 
rat heart in vivo26 were reversed by the NO synthase inhibitor L-NAME, but not by the 
cyclo-oxygenase inhibitor indomethacin (Figure 1).  
 
 
Figure 1. Effects of 10 min-intravenous 
infusions of angiotensin (Ang) II on 
myocardial conductance (=myocardial 
blood flow/mean arterial pressure) in 
rats pretreated with saline (open circles), 
L-NAME (10 mg/kg, followed by a 
continuous infusion of sodium 
nitroprusside to restore blood pressure 
to pre-L-NAME level; squares) or 
indomethacin (triangles). Data 
(mean±SEM) are obtained from Schuijt 
et al., 2001a and 2001b26,40. Note that 
the increase in conductance (indicative 
of vasodilation, and blocked by 
PD12331926  is reversed into a decrease 
by L-NAME (P=0.06) but not 
indomethacin.  
 
 
 
 
The exact location of vasodilator AT2 receptors in the vessel wall is still a matter of 
debate. The most likely site, in view of the stimulation of the bradykinin-B2 receptor-NO-
cGMP pathway, appears to be the endothelium. Heterodimerisation with vasoconstrictor 
AT1 receptors however would require the presence of AT2 receptors on vascular smooth 
muscle cells. Thus, perhaps AT2 receptors occur at multiple sites in the vessel wall.   
 
AT2 receptor-mediated effects in humans 
Data on AT2 receptor-mediated effects in humans are scarce. Gene variants of the AT2 
receptor are associated with left ventricular mass index in both young hypertensive 
males41 and females with hypertrophic cardiomyopathy,42 thereby supporting the 
antitrophic effect of AT2 receptors. AT2 receptors are upregulated in the human heart 
with interstitial fibrosis, and cardiac fibroblasts appear to be the major cell type for their 
expression.31,43  
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Intrabrachial infusion of the AT2 receptor antagonist PD123319 increased forearm 
vascular resistance in elderly women treated with the AT1 receptor antagonist 
candesartan,44 whereas Ang II tended to induce vasodilation in the forearm of healthy 
volunteers during AT1 receptor blockade.45 These data indirectly support the concept that 
AT2 receptors mediate vasodilation in human forearm resistance vessels. 
In large human coronary arteries (HCAs, diameter ≈ 4-5 mm), obtained from subjects 
who had died of non-cardiovascular causes, Ang II induced contractile responses that 
were fully blocked by the AT1 receptor antagonist irbesartan (Figure 2).46 PD123319 
modestly increased the contractile response to Ang II, but the difference was not 
significant. In contrast, in human coronary microarteries (HCMAs, diameter ≈ 200-300 
µm), PD123319 significantly increased the constrictor, AT1 receptor-mediated effects of 
Ang II (Figure 2).47 Moreover, Ang II relaxed preconstricted HCMAs in the presence of 
irbesartan, and this relaxation was prevented by PD123319. To the best of our 
knowledge, these data are the first to directly demonstrate AT2 receptor-induced 
vasorelaxation in humans. 
 
Figure 2. Contractions of large human coronary arteries (left panel) and human coronary 
microarteries (right panel) to angiotensin II in the absence (control, circles) or presence of 
irbesartan (triangles) or PD123319 (squares). Data (mean±SEM) are expressed as a percentage 
of the response to 100 mM K+ and have been obtained from MaassenVanDenBrink et al. (1999) 
and Batenburg et al. ( 2004b). Note the difference in scale. * P<0.05 vs. control 
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Radioligand binding studies and RT-PCR support the expression of AT2 receptors in 
HCMAs, HCAs and human coronary endothelial cells.47-49 The presence of AT2 receptors 
in HCAs, despite the non-significant effect of PD123319 on Ang II-induced 
vasoconstriction in these vessels, suggests either that their density in these arteries is 
lower, or that they mediate other (non-dilatory) effects, e.g., effects on vascular growth 
and remodelling.      
 
Mediators of AT2 receptor-mediated vasodilation in humans and the role of 
age, gender and endothelial function 
Endothelium removal, NOS blockade and B2 receptor blockade fully prevented the 
PD123319-induced potentiation of Ang II in HCMAs.47 Thus, AT2 receptor-mediated 
vasodilation in HCMAs depends on the activation of endothelial B2 receptors and NO, 
thereby fully supporting the animal data on this subject.7,22,37 The PD123319-induced 
effects correlated positively with age.47 Since endothelial function decreases with age 
(Figure 3), this could point to increased AT2 receptor expression in the face of decreased 
endothelial function, in agreement with the concept that AT2 receptor density increases 
under pathological conditions.31  
 
 
Figure 3. Correlation between age and
endothelial function (defined as the
substance P-induced relaxation of
preconstricted vessels) of human
coronary arteries (r=0.33, P<0.05). Data
are obtained from MaassenVanDenBrink
et al. (1999), Schuijt et al. (2003) and
Tom et al. (2003). 
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The maximal contractile response (Emax) to Ang II was larger in women than in men 
(Figure 4), but this did not affect the effect of PD123319. There are at least two 
explanations for the increased Emax in women. Men display higher renin levels50 and this 
could result, through increased Ang II levels, in AT1 receptor downregulation. Secondly, 
estrogens modulate AT1 receptor expression, which will directly affect Ang II-induced 
vasoconstriction.51 
 
A multivariate regression analysis of all (n=43) Ang II concentration-response curves in 
HCAs,46,52,53 entering age (range 5-58 years, mean±SEM 43±2.1 years), sex (21 women, 
22 men), cause of death (cerebrovascular accident, trauma, hypoxia), maximal contractile 
response (i.e., the response to 100 mmol/L K+, 49±3 mN) and endothelial function (i.e., 
substance P-induced relaxation of preconstricted vessels, 53±6%) as variables, confirmed 
that Ang II efficacy was larger in women than in men (21±3.1 vs. 14±2.1% of the 
response to 100 mmol/L K+, P<0.05), independently of all the above parameters. Ang II 
potency did not differ between men and women (pEC50 7.8±0.1 vs. 7.7±0.1), and 
correlated positively with endothelial function (P<0.02) independently of age, sex, cause 
of death and maximal contractile response. Thus, the more dysfunctional the 
endothelium, the more Ang II is needed to exert a certain vasoconstrictor effect. This 
observation is in agreement with a counterbalancing (AT2 receptor-mediated) effect 
under pathological conditions, even in vessels where the PD123319-induced effect is of 
modest proportion (Figure 2).   
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Bradykinin and vasodilatation: role of NO and EDHF 
The interaction between AT2 receptors and B2 receptor activation is not yet fully 
understood. Tsutsumi et al. (1999) proposed that Ang II decreases the intracellular pH in 
endothelial cells, which subsequently activates kininogenases that cleave bradykinin from 
intracellularly stored kininogens. It is difficult to conceive how this mechanism explains  
the AT2 receptor-mediated dilatation of isolated vessels mounted in organ baths, since 
ACE inhibitors do not induce vasodilation in such vessels, thereby arguing against the 
presence of endogenous bradykinin in isolated vessels.54-56 One possibility is that AT2 
receptors and B2 receptors heterodimerize and interact in a bradykinin-independent 
manner.  
B2 receptor activation results in NO synthesis by endothelial NOS, and NO relaxes 
vascular smooth muscle cells through guanylyl cyclase activation and subsequent cGMP 
generation.54,57,58 Thus, if B2 receptors are indeed involved in the relaxant effect mediated 
by AT2 receptors, it is not surprising that AT2 receptor activation results in cGMP 
accumulation. NOS inhibitors however do not completely block bradykinin-induced 
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Figure 4. Contractions of human coronary microarteries obtained from men (left panel, n=12)
and women (right panel, n=10) to angiotensin II in the absence (control, circles) or presence of
PD123319 (squares). Data (mean±SEM) are expressed as a percentage of the response to 100
mM K+ and have been obtained from Batenburg et al. (2004b). Note that the maximum
contraction is larger in women than in men (P=0.05), but that the effect of PD123319 is
observed in both sexes. 
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vasorelaxation, suggesting the existence of either NO-storage sites59,60 or a non-NO 
‘endothelium-derived hyperpolarizing factor’ (EDHF).61  
EDHF-mediated responses in different arteries have been linked to K+, cytochrome-P450 
products from arachidonic acid (epoxyeicosatrienoic acids (EETs), in particular 5,6-EET, 
11,12-EET and 14,15-EET), prostacyclin and H2O2.62-67 The identity of EDHF and its 
contribution to overall relaxation appear to differ between species, between vascular beds 
and between vessels of different sizes.68 In general, de novo synthesized NO is of greater 
importance in large arteries than in microarteries (Figure 5).    
Busse et al.61 recently summarized all currently available data on EDHF and proposed 
that EDHF-mediated relaxation depends on the activation of endothelial intermediate- 
and small-conductance Ca2+-activated K+-channels (IKCa, SKCa).69,70 Such activation 
results in the release of K+ into the myoendothelial space, which subsequently induces 
smooth muscle hyperpolarization by activating inwardly rectifying K+ channel (KIR) 
channels and/or Na+-K+-ATPase (Figure 6). According to this concept, EETs regulate 
endothelial hyperpolarization as well as the spread of this hyperpolarization to the 
adjacent smooth muscle cells through myoendothelial gap junctions. In addition, EETs 
directly activate large-conductance Ca2+-activated K+-channels (BKCa) on smooth muscle 
cells.71 With regard to the latter, it is important to note that NO itself is capable of 
inducing hyperpolarization via activation of Ca2+-activated K+ channels in vascular 
smooth muscle.72 Interestingly, AT2 receptor-induced relaxation of rat mesenteric 
microvessels has also been reported to depend on opening of BKCa channels.24  
Chapter 1 
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Data obtained in human and porcine coronary microarteries fully agree with the 
unifying EDHF concept proposed by Busse et al..57,58 Bradykinin-induced relaxation of 
these vessels was found to depend on 1) endothelial IKCa and SKCa channels, and 2) the 
activation of guanylyl cyclase, KIR channels and Na+/K+ ATPase. Activation of Ca2+-
activated K+-channels occurred by a factor other than NO. In HCMAs, this factor was not 
a cytochrome P450 epoxygenase product or H2O2. Since NO scavengers blocked 
bradykinin-induced relaxations of coronary arteries to a greater degree than NOS 
inhibitors,54,58,73 whereas increasing the concentration of the NOS inhibitor did not yield 
additional blocking effects,58,73 one possibility is that this factor is a NO-containing factor 
from a source that does not depend on the acute conversion of L-arginine by NOS. 
NO-containing factors are thought to mediate light-induced photorelaxation of vascular 
smooth muscle cells.43,74 Nitrosothiol-depleting agents reduce photorelaxation responses,74 
and S-nitrosothiols have therefore been proposed to mediate this phenomenon.  
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Figure 5. Relaxations of large porcine coronary arteries (left panel) and porcine coronary
microarteries (right panel), following preconstriction with prostaglandin F2α or U46619, to
bradykinin in the absence (control) or presence of 100 µM L-NAME and/or 100 nM
charybdotoxin (char) + 100 nM apamin (apa). Data (mean±SEM) are expressed as a percentage
of preconstriction and have been obtained from Danser et al. (2000) and Batenburg et al.
(2004c). Note that the rightward shift induced by L-NAME is much larger in large coronary
arteries, supporting a more important role for NO in these arteries. 
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S-nitrosothiols induce relaxation not only through their decomposition to NO,75 but also 
by activating stereoselective recognition sites.76 Recently, the cysteine residues within the 
α subunit of the BKCa channel were identified as a S-nitrosothiol binding site.77 In support 
of the concept that S-nitrosothiols mediate bradykinin-induced, EDHF-dependent 
relaxations, the nitrosothiol-depleting agent p-hydroxymercurobenzoic acid reduced the 
relaxant effects of bradykinin in porcine coronary arteries.78 Furthermore, the S-
nitrosothiol L-S-nitrosocysteine activated endothelial IKCa and SKCa channels (Figure 7) 
and hyperpolarized smooth muscle cells.58  
The effect of NO blockade on bradykinin-induced relaxation of HCMAs was larger in 
men than in women (Figure 8). This suggests that the contribution of EDHF is larger in 
women. Similar observations were made in rat arteries, where it was simultaneously 
demonstrated that estrogens directly upregulate the EDHF pathway, without altering NOS 
expression.79,80 The reduced efficacy of Ang II in coronary arteries of men compared to 
women (Figure 4) may also relate to this phenomenon. 
     
 
 
 
 
 
 
 
 
Figure 7. Relaxations of large porcine coronary arteries (left panel) and porcine coronary
microarteries (right panel), following preconstriction with U46619, to the S-nitrosothiol L-S-
nitrosocysteine (L-SNC) in the absence (control, circles) or presence of 100 nM charybdotoxin +
100 nM apamin (squares). Data (mean±SEM) are expressed as a percentage of preconstriction
and have been obtained from Batenburg et al. (2004d, c). 
 
56789
0
20
40
60
80
100
- log [L-SNC] (M)
%
 re
la
xa
tio
n
456789
0
20
40
60
80
100
120
- log [L-SNC] (M)
  General introduction 
 21
 
Aim of this thesis 
The release of paracrine factors from endothelial cells is a critical determinant of vascular 
tone. Endothelium-dependent vasodilators such as acetylcholine and bradykinin stimulate 
endothelial cells to release the vasodilators NO and/or endothelium-derived 
hyperpolarizing factor (EDHF). The relative contribution of each of these mediators to 
endothelium-dependent vasodilation is related to vessel size: NO-mediated responses 
predominate in conduit arteries, whereas EDHF is more prominent in resistance vessels.68 
The latter vessels, with a diameter <400 µm, are the main contributors to peripheral 
vascular resistance.  
Animal studies have recently shown that angiotensin (Ang) II, in addition to being a 
potent vasoconstrictor, is also capable of causing vasorelaxation, most likely in an 
endothelium-dependent manner (involving both bradykinin and NO).81 Consequently, the 
net effect of Ang II depends on the ratio of the Ang II receptors mediating constriction 
(Ang II type 1, AT1) and relaxation (Ang II type 2, AT2). Possibly, these receptors 
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Figure 8. Relaxations of human coronary microarteries, following preconstriction with U46619,
to bradykinin in men (left panel, n=8) and women (right panel, n=12) in the presence (control,
circles) or absence of NO (triangles). Data (mean±SEM) are expressed as a percentage of
preconstriction and have been obtained from Batenburg et al. (2004a). Note that the rightward
shift induced by NO removal (with either L-NAME or hydroxocobalamin) is larger in men
(P=0.003) than in women (P=0.01). 
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interact as a consequence of heterodimerization,35 similar to the interaction that has been 
reported previously between AT1 receptors and other vasoconstrictor receptors, e.g., 
endothelin-1 receptors82 and α1-adrenoceptors.83 
It was the aim of the current thesis to investigate Ang II-dependent vasodilatation in 
humans, focussing in particular on the AT2 receptor – bradykinin – NO/EDHF pathway 
(Chapter 2). We also tried to obtain more detailed information on the nature of EDHF, by 
studying bradykinin-induced relaxation during NO synthase (NOS) blockade in both 
human and porcine coronary (micro-)arteries (Chapters 3-5). Finally, we investigated the 
(heterodimeric) interaction between AT1 and α1-adrenoceptors in human microarteries, in 
order to obtain a better understanding of the mechanism of action of the Ang II-inhibiting 
properties of the non-selective β- and α1-adrenoceptor antagonist carvedilol (Chapter 6). 
All human studies were performed in coronary microarteries (diameter <500 µm) 
obtained from heart valve donors, and mounted in Mulvany myographs. The porcine 
vessels that were used in this thesis were either large coronary arteries or coronary 
microarteries. All studies were complemented by simultaneous biochemical and 
molecular-biological measurements in vascular segments, in order to determine the 
contributing second messengers and receptor subtypes.   
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Angiotensin II type 2 receptor-mediated vasodilation in 
human coronary microarteries 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Circulation 2004; 109: 2296-2301 
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Summary 
 
Angiotensin (Ang) II type 2 (AT2) receptor stimulation results in coronary vasodilation in 
the rat heart. In contrast, AT2 receptor-mediated vasodilation could not be observed in 
large human coronary arteries. Here we studied Ang II-induced vasodilation of human 
coronary microarteries (HCMAs). HCMAs (diameter 160-500 µm) were obtained from 
49 heart valve donors (age 3-65 years) and mounted in Mulvany myographs. Ang II 
constricted HCMAs in a concentration-dependent manner (pEC50 8.6±0.2; maximal effect 
(Emax) 79±13 % of the contraction to 100 mmol/L K+). The Ang II type 1 receptor 
antagonist irbesartan prevented this vasoconstriction, whereas the AT2 receptor 
antagonist PD123319 increased Emax to 97±14% (P<0.05). The increase in Emax was 
larger in older donors (correlation ∆Emax vs. age r=0.47, P<0.05). The PD123319-induced 
potentiation was not observed in the presence of the NO synthase inhibitor L-NAME, the 
bradykinin type 2 (B2) receptor antagonist Hoe140 or after removal of the endothelium. 
Ang II relaxed U46619-preconstricted HCMAs in the presence of irbesartan by 
maximally 48±16%, and PD123319 prevented this relaxation. Finally, radioligand 
binding studies and RT-PCR confirmed the expression of AT2 receptors in HCMAs.  In 
conclusion, AT2 receptor-mediated vasodilation in the human heart appears to be limited 
to coronary microarteries, and is mediated via B2 receptors and NO. Most likely, AT2 
receptors are located on endothelial cells and their contribution increases with age. 
  AT2 receptor-mediated vasodilation 
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Introduction 
 
Angiotensin (Ang) II type 2 (AT2) receptors are believed to mediate vasodilation, 
although data to support this concept in humans are not available. Neither in vitro studies 
investigating Ang II-induced vasoconstriction in isolated human coronary arteries46 and 
saphenous veins,84 nor in vivo studies investigating Ang II-induced vasoconstriction in 
the forearm vascular bed of healthy volunteers,45,85 provided evidence for AT2 receptor-
mediated vasodilation. In contrast, both in vitro and in vivo studies in rats and mice 
support this notion.5,20,24,26,86,87 One explanation for the discrepancy between the lack of 
AT2 receptor-mediated vasodilation in human coronary arteries,46 and the occurrence of 
such dilation in the rat coronary vascular bed,26 is that AT2 receptors are located in 
coronary microarteries only. In the present study we therefore investigated AT2 receptor-
induced vasodilation in human coronary microarteries (HCMAs) mounted in Mulvany 
myographs. We also investigated whether endothelial NO and/or bradykinin type 2 (B2) 
receptors mediate such vasodilation in HCMAs, since studies in animals support this 
possibility.5,22,33,88 Finally, we verified, both through radioligand binding studies and RT-
PCR, whether HCMAs express AT2 receptors.   
 
Methods 
 
Human tissue collection 
HCMAs were obtained from 49 heart-beating organ donors (22 men, 27 women, age 3-65 
years, mean 45 years), who died of non-cardiac causes (3 cerebrovascular accident, 9 
head trauma, 21 subarachnoid bleeding, 4 post-anoxic encephalopathy, 12 intracranial 
bleeding) <24 hours before the heart was taken to the laboratory. Hearts were provided by 
the Rotterdam Heart Valve Bank after removal of the heart valves for transplantation 
purposes. The study was approved by the Ethics Committee of the Erasmus MC. The 
hearts were stored in an ice-cold sterile organ-protecting solution after circulatory arrest. 
After arrival at the laboratory, a tertiary branch of the left anterior descending coronary 
artery (diameter 160-500 µm, mean 360 µm) was removed and stored overnight in a cold 
(4°C), oxygenated Krebs bicarbonate solution of the following composition (mmol/L): 
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NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 
7.4. In addition, HCMAs, right epicardial coronary arteries and/or pieces of left 
ventricular tissue from 29 hearts were frozen in liquid nitrogen for mRNA determinations 
or radioligand binding studies.  
 
Myograph studies 
Following overnight storage, HCMAs were cut into segments of approximately 2 mm 
length and mounted in a Mulvany myograph (J.P. Trading) with separated 6-mL organ 
baths containing oxygenated Krebs at 37°C. The Krebs was continuously aerated with 
95% O2 and 5% CO2, and tissue responses were measured as changes in isometric force, 
using a Harvard isometric transducer. Following a 30-min stabilization period, the 
optimal internal diameter was set to a tension equivalent to 0.9 times the estimated 
diameter at 100 mm Hg effective transmural pressure as described by Mulvany and 
Halpern.89 In some vessels, the endothelium was removed by gently rubbing a hair 
through the lumen of the mounted artery. Endothelial integrity or removal was verified by 
observing relaxation (or lack thereof) to 10 nmol/L substance P after preconstriction with 
10 nmol/L of the thromboxane A2 (TxA2) analogue U46619 (Sigma). Subsequently, to 
determine the maximum contractile response, the tissue was exposed to 100 mmol/L KCl. 
The segments were then allowed to equilibrate in fresh organ bath fluid for 30 min. Next, 
segments were pre-incubated for 30 min with the Ang II type 1 (AT1) receptor antagonist 
irbesartan (1 µmol/L, a gift of Bristol-Myers Squibb),46 the AT2 antagonist PD123319 (1 
µmol/L, a gift of Parke-Davis),13 the B2 receptor antagonist Hoe140 (1 µmol/L, a gift of 
Hoechst)54 and/or L-NAME (100 µmol/L, Sigma). Thereafter, concentration-response 
curves (CRCs) were constructed to Ang II, either directly or following preconstriction 
with 10 nmol/L U46619 to 60% of the maximum contractile response. A higher 
concentration of U46619 (30 nmol/L) was required in segments that had been pre-
incubated with irbesartan, because irbesartan antagonizes TxA2 receptors.90 The cyclo-
oxygenase inhibitor indomethacin (5 µmol/L) was present during the entire experiment to 
suppress spontaneously occurring contractions and relaxations. 
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Cyclic GMP measurement 
To study Ang II-induced cGMP production, vessel segments (5-10 mg) were exposed to 
1 µmol/L Ang II in 10 mL oxygenated Krebs bicarbonate solution for 1 min at 37ºC in 
the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthine (100 
µmol/L), following a 30-min preincubation without (control) or with 1 µmol/L 
PD123319 or irbesartan. Tissues were then frozen in liquid nitrogen, and stored at -80ºC. 
To determine cGMP, frozen tissues were homogenized in 0.5 mL 0.1 mol/L HCl using a 
stainless steel ultraturrax (Polytron). Homogenates were centrifuged at 3300 g, and 
cGMP was measured in 300 µL supernatant by ELISA following acetylation (R&D 
Systems). Results are expressed as pmol/mg protein. The lower limit of detection was 0.1 
pmol/mg protein. 
 
Radioligand binding studies 
Sarcolemmal membrane fractions were prepared from HCMAs and porcine adrenal 
glands as described before.91 The adrenals were obtained from three 2-3 month old pigs 
that had been used in in-vivo experiments investigating the effects of calcitonin gene-
related peptide receptor (ant)agonists.92 125I-Ang II, prepared with the chloramine T-
method (specific activity 2200 Ci/mmol),93 was used as the radioligand. Assays were run 
for 60 minutes at 18°C in 30 µL Tris buffer (50 mmol/L), 40 µL membrane fraction 
(containing 100 µg protein, determined by the Bradford assay as described before13) and 
30 µL radioligand (final volume: 100 µL). Non-specific binding, AT1 receptor-specific 
binding and AT2 receptor-specific binding were determined by repeating the experiment 
in the presence of Ang II (at a concentration 100 times the concentration of 125I-Ang II), 
irbesartan (0.3 pmol/L-0.3 mmol/L) and PD123319 (0.3 pmol/L-0.3 mmol/L), 
respectively. Incubation was stopped by adding 4 mL ice-cold phosphate-buffered saline 
(PBS), pH 7.4. Samples were then filtered through a Whatman GF/B filter. Filters were 
washed twice with 4 mL ice-cold PBS, and filter-bound radioactivity was measured in a 
gamma-counter.  
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AT1 and AT2 receptor mRNA 
Total RNA was isolated from HCMAs, right epicardial coronary arteries and left 
ventricular tissue using the Trizol reagent (Gibco-BRL). RT-PCR was performed 
according to standard procedures and 35 cycles of amplification, using primer sequences 
as follows: AT1 receptor sense 5’-CTT TTC CTG GAT TCC CCA C-3’, and antisense 
5’-CTT CTT GGT GGA TGA GCT TAC-3’, AT2 receptor sense 5’-GTG ACC AAG 
TCC TGA AGA TG-3’ and antisense 5’-CAC AAA GGT CTC CAT TTC TC-3’, 
resulting in amplification products of 304 and 335 bp, respectively. Positive and negative 
controls were mRNAs extracted from human liver, a human breast carcinoma cell line 
(MCF7) and a human colon carcinoma cell line (SW480).94 The absence of non-specific 
amplification was verified by running RT-PCR and PCR amplifications without adding 
tissue extracts. As controls for RNA quality, amplification reactions were performed 
using pairs of primers specific for glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH).95 Amplified transcripts were analyzed on 2% agarose gels. 
 
Data analysis 
Data are given as mean±SEM. Contractile or relaxant responses are expressed as a 
percentage of the contraction to 100 mmol/L K+ or U46619. CRCs were analyzed as 
described to obtain pEC50 (-10logEC50) values.46 Statistical analysis was by paired t-test, 
once one-way ANOVA, followed by Dunnett’s post-hoc evaluation, had revealed that 
differences existed between groups. P<0.05 was considered significant.  
 
Results 
 
Myograph studies 
Ang II constricted HCMAs in a concentration-dependent manner (pEC50 8.6±0.2, n=22) 
with a maximal response (Emax) of 79±13% (Figure 1). Irbesartan nearly completely 
blocked the Ang II-mediated constriction. PD123319 increased Emax to 97±14% (P<0.05). 
PD123319 did not affect the potency of Ang II (pEC50=8.7±0.2, n=22), although in 11 
experiments a leftward shift of the Ang II CRC (i.e., an increase in the pEC50 value of 0.2 
or more) was observed in the presence of the AT2 receptor antagonist.  
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The PD123319-dependent increase in Emax was larger in older donors (r=0.47, P<0.05; 
Figure 2). The increase in Emax was largest in the 11 experiments where PD123319 
induced a leftward shift of the Ang II CRC: +34±10% vs. +2.2±8.4% in the experiments 
where PD123319 induced either no (i.e., ∆pEC50 <0.2; n=7) or a rightward (i.e., pEC50 
decreased by 0.2 or more; n=4) shift of the Ang II CRC. 
L-NAME increased baseline contraction to 20-30% of the maximum response to 100 
mmol/L K+ and prevented the PD123319-induced potentiation of Ang II (Figure 3). 
Potentiation was also not observed following removal of the endothelium and in the 
presence of Hoe140 (Figure 3).  
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Figure 1. Contractions of HCMAs to Ang
II in the absence (control; circles) or
presence of irbesartan (triangles) or
PD123319 (squares). Contractions
(mean±SEM; n=5-22) are expressed as
a percentage of the response to 100
mmol/L K+. * P<0.05 vs control. 
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Figure 2.  Correlation between donor age 
and the change in Emax (∆Emax) of the Ang 
II CRC observed following the addition of 
PD123319 to the organ bath (n=22). 
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Figure 3. Contractions of HCMAs to Ang II in the absence (circles) or presence of PD123319
(squares) following pretreatment with L-NAME, endothelium removal, or pretreatment with
Hoe140. Contractions (mean±SEM; n=3-7) are expressed as a percentage of the response to
100 mmol/L K+. 
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Following preconstriction with U46619 (to approximately 60% of the maximum response 
to 100 mmol/L K+), Ang II caused a marginal further increase (P=NS) in contraction 
(Figure 4). This response was unaltered by PD123319 and reversed into a relaxation (by 
maximally 49±16%) in the presence of irbesartan. PD123319 fully prevented the latter 
relaxation. Without Ang II, U46619-induced preconstrictions in the presence of 
irbesartan remained stable for at least 60 min (data not shown). Thus, the Ang II-induced 
relaxations under these conditions cannot be attributed to TxA2 receptor antagonism by 
irbesartan.90    
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Figure 4. Left, response of U46619-preconstricted HCMAs to Ang II in the absence or presence
of irbesartan, PD123319 or irbesartan + PD123319. Data (mean±SEM; n=2-5) are expressed as
a percentage of the response to U46619. Right, original tracing of an experiment in which an
U46619-preconstricted HCMA was exposed to Ang II under control conditions (A), or following
pre-incubation with PD123319 (B), irbesartan (C), or irbesartan + PD123319 (D). Ang II
concentrations were increased with half log steps, starting at 1 nmol/L (9) and ending at 1
µmol/L (6). 
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Cyclic GMP measurement 
Ang II did not significantly increase microvascular cGMP (Figure 5; n=8, P=0.11 vs. 
control), neither alone, nor in the presence of PD123319 or irbesartan.  
 
Radioligand binding studies 
The total amount of protein in the HCMA sarcolemmal membrane fraction (≈500 µg), 
prepared from vessel segments of 19 subjects, was too small to study a wide range of 
conditions. We therefore used sarcolemmal membrane fractions prepared from 6 porcine 
adrenal glands to obtain the most optimal conditions to demonstrate the presence of AT2 
receptors in HCMAs. Following a 1-hour incubation with 125I-Ang II (final concentration 
in the incubation mixture: 0.5 nmol/L), total and non-specific 125I-Ang II binding to 
porcine adrenal membranes amounted to 4660±150 and 2100±80 cpm/100 µg protein 
(n=8), respectively. PD123319 and irbesartan abolished specific binding in a 
concentration-dependent manner (Figure 6, panel A). The inhibitor concentration 
required to reduce specific binding by 50% (IC50) was 50±1 nmol/L for PD123319. This 
value mimics the IC50 of PD123319 obtained in previous experiments with cells 
expressing AT2 receptors only.96 In contrast, the IC50  
Figure 5. Cyclic GMP levels
(mean±SEM; n=8) in HCMAs at
baseline and after a 1-min exposure to
Ang II under control conditions (no
antagonist) and in the presence of
irbesartan or PD123319. 
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of irbesartan in the present study (20±1 µmol/L) exceeded its IC50 in cells exclusively 
expressing AT1 receptors by three orders of magnitude.97 Taken together, these data 
suggest that our porcine adrenal membrane fraction contained predominantly AT2 
receptors. A PD123319 concentration of 10 µmol/L is required to fully block 125I-Ang II 
binding to these receptors.  
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Figure 6. Panels A and B. Displacement of specifically bound 125I-Ang II by irbesartan or
PD123319 in sarcolemmal membrane fractions prepared from 6 porcine adrenal glands (A) and
19 HCMAs (B). Panel C. Results from the RT-PCR amplification of AT1 receptor mRNA (304
bp), AT2 receptor mRNA (335 bp), and GAPDH mRNA in HCMAs (lanes 1-3), large epicardial
human coronary arteries (lanes 4-6) and human left ventricular tissue (lanes 7-9) obtained from
5 hearts. Positive controls (T+) for AT1 - and AT2 receptor mRNA are extracts of human liver and
human breast carcinoma cells (MCF7), respectively. Negative controls (T-) for AT1 - and AT2
receptor mRNA are extracts of human breast carcinoma cells (MCF7) and colon carcinoma cells
(SW480), respectively. Bl RT-PCR and Bl PCR represent the results of RT-PCR or PCR
amplifications performed in the absence of added tissue extracts (to exclude contamination).   
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Based on these findings, as well as on previous studies investigating irbesartan 
concentrations that selectively block AT1 receptors,97,98 we incubated HCMA membranes 
with 0.5 nmol/L 125I-Ang II, in the absence or presence of 50 nmol/L Ang II, 10 µmol/L 
PD123319, or 1 µmol/L irbesartan. Ang II reduced 125I-Ang II binding from 1813 to 1175 
cpm/100 µg protein. PD123319 and irbesartan both reduced specific binding by 
approximately 50%, thereby indicating that HCMAs contain AT1 as well as AT2 
receptors (Figure 6, panel B).   
 
AT1 and AT2 receptor mRNA 
RT-PCR revealed expression of AT1 and AT2 receptors in HCMAs, large epicardial 
coronary arteries and/or left ventricular tissue from 5 hearts (Figure 6, panel C). Similar 
data were obtained in an additional HCMAs from 7 hearts (data not shown). 
 
Discussion 
 
This study is the first to show AT2 receptor-mediated vasodilation in human blood 
vessels. Evidence for this effect was obtained in two ways. First, the AT2 receptor 
antagonist PD123319, at a concentration that has been reported to result in complete 
blockade of AT2 receptor-mediated effects,13 increased the maximal contractile response 
to Ang II, thereby indirectly demonstrating that AT2 receptor stimulation counteracts AT1 
receptor-mediated vasoconstriction. Second, during AT1 receptor blockade with 
irbesartan (allowing selective AT2 receptor stimulation) Ang II relaxed preconstricted 
HCMAs and this was prevented by PD123319. Such vasodilation was not observed in 
quiescent HCMAs in the presence of irbesartan, probably because vasodilator responses 
are more difficult to detect without preconstriction. Based on these data, it is clear that, at 
least in HCMAs, the net contractile effect of Ang II is determined by the magnitude of 
the response mediated via AT1 (contraction) and AT2 (relaxation) receptors.  
In addition to its effect on Emax, PD123319 caused a leftward shift of the Ang II CRC in 
≈50% of the experiments. Such increased potency of Ang II in the presence of PD123319 
is not due to an effect of the AT2 receptor antagonist on Ang II metabolism.53,98 It could 
point to more efficient AT1 receptor signal transduction during AT2 receptor blockade. 
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Furthermore, a recent study has suggested that AT1 and AT2 receptors form 
heterodimers.35 An alternative explanation for the increased potency might therefore be 
that in some donors AT1 receptor-AT2 receptor heterodimers exist which bind Ang II 
with higher affinity during AT2 receptor blockade. The underlying assumption for this 
explanation is however that AT1 and AT2 receptors in these donors are located on the 
same cell.  
The increase in Emax was larger in older donors, suggesting that the contribution of AT2 
receptors increases with age. Although AT2 receptor density increases under pathological 
conditions,88 the donors in the present study died of non-cardiac causes and did not use 
cardiovascular medication. Thus, it is unlikely that the increased Emax during AT2 
receptor blockade in older donors simply reflects the occurrence of cardiovascular 
disorders in these subjects. It might reflect a general decrease of vascular function with 
age.  
In an earlier study in large epicardial human coronary arteries we were unable to detect 
AT2 receptor-mediated vasodilation,46 whereas vasodilation did occur in the rat coronary 
vascular bed.26 The present study solves this discrepancy, by demonstrating that AT2 
receptor-mediated vasodilation is limited to coronary microarteries. Importantly, AT2 
receptor expression in HCMAs could be demonstrated by both RT-PCR and radioligand 
binding experiments. Unexpectedly, AT2 receptor mRNA was also detected by RT-PCR 
in large coronary arteries. This would imply that either the AT2 receptor density in large 
coronary arteries is too low to allow detection of vasodilation in the organ bath setup, or 
that AT2 receptors in these arteries mediate other (non-dilatory) effects, e.g., effects on 
vascular growth and remodeling.99,100 AT2 receptor expression has been demonstrated 
before in the human myocardium, including the coronary vascular bed.31,48  
The mechanism underlying AT2 receptor-mediated vasodilation in HCMAs is currently 
unknown. AT2 receptors themselves may act as AT1 receptor antagonists, independently 
of Ang II.35 This would require their occurrence on the same cell, as discussed above. 
Furthermore, B2 receptors, NO, cGMP, Ca2+-activated K+ channels and/or phosphatases 
have been implicated in AT2 receptor-induced effects.5,18,22,24,33,87,88,101 Our data with L-
NAME and Hoe140 in HCMAs support a role for B2 receptors and NO. Since the 
vasodilator effects in HCMAs were observed in the presence of indomethacin, 
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prostaglandins do not appear to be involved. The lack of effect of PD123319 in de-
endothelialized segments confirms the contribution of endothelial B2 receptor-induced 
NO release, and simultaneously suggests that AT2 receptors in HCMAs are located on 
endothelial cells. In agreement with this concept, cultured human coronary artery 
endothelial cells do express AT2 receptors.49  
Taken together, the most likely scenario to explain our results is that Ang II stimulates 
endothelial AT2 receptors in HCMAs. This results in endothelial B2 receptor activation 
and NO release. NO subsequently activates guanylyl cyclase in vascular smooth muscle 
cells, thereby counteracting the contractile responses mediated via the AT1 receptors on 
these cells. Guanylyl cyclase generates cGMP, and although the Ang II-induced (AT2 
receptor-mediated) increase in the microvascular cGMP content in the present study was 
not significant, the tendency of PD123319 (but not irbesartan) to block this increase 
mimics similar observations in rat aorta and rat uterine arteries.5,18 The lack of 
significance in the present experiments most likely relates to the modest (≈30%) increase 
in cGMP content induced by Ang II as compared to other agonists. For instance, in our 
experimental setup, 1 µmol/L bradykinin increased microvascular cGMP 7±2 fold (n=4, 
data not shown).     
In conclusion, AT2 receptor-mediated vasodilation occurs in the coronary 
microcirculation of non-diseased human hearts in an endothelium-dependent manner, and 
is mediated via B2 receptors and NO. This finding could be of clinical relevance, not only 
because cardiac AT2 receptors are upregulated under pathological conditions,31 but also 
because animal studies have shown that the beneficial effects of AT1 receptor antagonists, 
in contrast to those of ACE inhibitors, depend on AT2 receptor stimulation.11,12 
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Summary 
 
To investigate the mediators of bradykinin-induced vasorelaxation in human coronary 
microarteries (HCMAs), HCMAs (diameter ≈300 µm), obtained from 42 heart valve 
donors (20 men, 22 women, age 3-65 years, mean 46 years) were mounted in Mulvany 
myographs. In the presence of the cyclo-oxygenase inhibitor indomethacin, bradykinin 
relaxed preconstricted HCMAs (pEC50 8.2±0.1). L-NAME and ODQ (inhibitors of NO 
synthase and guanylyl cyclase, respectively), and the NO scavenger hydroxocobalamin, 
alone or in combination, shifted the bradykinin concentration-response curve (CRC) to 
the right. Removal of H2O2 (with catalase), inhibition of cytochrome P450 epoxygenase 
(with sulfaphenazole or clotrimazole) or gap junctions (with 18α-glycyrrhetinic acid or 
carbenoxolone), and blockade of large- (BKCa) and small-conductance (SKCa) Ca2+-
dependent K+-channels (with iberiotoxin and apamin), either alone or on top of 
hydroxocobalamin, did not affect bradykinin. In contrast, complete blockade of 
bradykinin-induced relaxation was obtained when combining the non-selective large- and 
intermediate-conductance (IKCa) Ca2+-dependent K+-channel blocker charybdotoxin and 
apamin with hydroxocobalamin, whereas charybdotoxin + apamin alone were without 
effect. Inhibition of inwardly rectifying K+ channels (KIR) and Na+/K+ ATPase (with 
BaCl2 and ouabain, respectively) shifted the bradykinin CRC 10-fold to the right, but did 
not exert an additional effect on top of hydroxocobalamin. In conclusion, bradykinin-
induced relaxation in HCMAs depends on 1) the activation of guanylyl cyclase, KIR, and 
Na+/K+ ATPase by NO, and 2) IKCa and SKCa channels. The latter are activated by a 
factor other than NO. This factor is not a cytochrome P450 epoxygenase product or H2O2, 
nor does it depend on gap junctions or BKCa.   
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Introduction 
 
Endothelium-dependent relaxation induced by bradykinin cannot fully be attributed to the 
release of nitric oxide (NO). In resistance-sized vessels a large proportion of 
endothelium-derived relaxation involves the release of endothelium-derived 
hyperpolarizing factors (EDHFs).68 Putative EDHF candidates are prostacyclin, S-
nitrosothiols, K+, cytochrome-P450 products of arachidonic acid (epoxyeicosatrienoic 
acids, EETs) and hydrogen peroxide (H2O2),54,63-65,67,71,102, and EDHF-dependent responses 
have been reported to involve large-, intermediate- and/or small-conductance Ca2+-
activated K+ channels (BKCa, IKCa, SKCa), inwardly rectifying K+ (KIR) channels, Na+-K+-
ATPase and gap junctions.61,64,65,71,103 
Busse et al.61 recently summarized all currently available data on EDHF and proposed 
that EDHF-mediated relaxation (i.e., relaxation observed in the absence of NO) depends 
on the activation of endothelial IKCa and SKCa channels.64 Such activation results in the 
release of K+ into the myo-endothelial space, which subsequently induces smooth muscle 
hyperpolarization by activating KIR channels, Na+-K+-ATPase and/or BKCa channels.64 
According to this concept, EETs regulate endothelial hyperpolarization as well as the 
spread of this hyperpolarization to the adjacent smooth muscle cells through myo-
endothelial gap junctions. In addition, EETs may directly activate BKCa channels on 
smooth muscle cells.71   
In the present study we set out to verify the above concept in human coronary 
microarteries (HCMAs). Bradykinin has already been reported to hyperpolarize smooth 
muscle cells in human coronary arteries,104 and this hyperpolarization could not be 
attributed to NO.73,105  
 
Methods 
 
Human tissue collection 
HCMAs were obtained from 42 heart beating organ donors (20 men, 22 women, age 3-65 
years, mean 46 years), who died of non-cardiac causes (3 cerebrovascular accident, 11 
head trauma, 18 subarachnoidal bleeding, 3 post-anoxic encephalopathy, 7 intracranial 
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bleeding) <24 hours before the heart was taken to the laboratory. Hearts were provided by 
the Rotterdam Heart Valve Bank after removal of the heart valves for transplantation 
purposes. The study was approved by the Ethics Committee of the Erasmus MC. The 
hearts were stored in an ice-cold sterile organ-protecting solution after circulatory arrest. 
After arrival at the laboratory, a tertiary branch of the left anterior descending coronary 
artery (diameter 160-600 µm, mean 380 µm) was removed and stored overnight in a cold 
(4°C), oxygenated Krebs bicarbonate solution of the following composition (mmol/L): 
NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 
7.4. 
 
Myograph studies 
Following overnight storage, HCMAs were cut into segments of approximately 2 mm 
length and mounted in a Mulvany myograph (J.P. Trading) with separated 6-mL organ 
baths containing Krebs bicarbonate solution, aerated with 95% O2 and 5% CO2, and 
maintained at 37 °C. Tissue responses were measured as changes in isometric force, 
using a Harvard isometric transducer. Following a 30-min stabilization period, the 
optimal internal diameter was set to a tension equivalent to 0.9 times the estimated 
diameter at 100 mm Hg effective transmural pressure as described by Mulvany and 
Halpern.89 Endothelial integrity was verified by observing relaxation to 10 nmol/L 
substance P after preconstriction with 10 nmol/L of the thromboxane A2 analogue 
U46619. Subsequently, to determine the maximum contractile response, the tissue was 
exposed to 100 mmol/L KCl. The segments were then allowed to equilibrate in fresh 
organ bath fluid for 30 min in the absence or presence of one or more of the following 
inhibitors: the bradykinin type 2 (B2) receptor antagonist Hoe140 (1 µmol/L), the NO 
synthase inhibitor L-NAME (100 µmol/L), the NO scavenger hydroxocobalamin (200 
µmol/L), the guanylyl cyclase inhibitor ODQ (10 µmol/L), the IKCa + BKCa channel 
inhibitor charybdotoxin (100 nmol/L), the SKCa channel inhibitor apamin (100 nmol/L), 
the BKCa channel inhibitor iberiotoxin (100 nmol/L), the inwardly rectifying K+ channel 
(KIR) inhibitor BaCl2 (30 µmol/L), the Na+-K+-ATPase inhibitor ouabain (1 mmol/L), the 
H2O2 inhibitor catalase (1000 units/ml), the cytochrome P450 epoxygenase inhibitors 
sulfaphenazole (10 µmol/L) and clotrimazole (50 µmol/L), or the gap junction inhibitors 
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18α-glycyrrhetinic acid (10 µmol/L) and carbenoxolone (100 µmol/L). Vessels were then 
preconstricted with U46619 (3-30 nmol/L), and concentration-response curves (CRCs) 
were constructed to bradykinin. The cyclo-oxygenase inhibitor indomethacin (5 µmol/L) 
was present during all experiments to suppress spontaneously occurring contractions and 
relaxations. 
 
Cyclic GMP (cGMP) Measurement 
To study bradykinin-induced cGMP production, vessel segments (5-10 mg) were exposed 
to 1 µmol/L bradykinin in 10 mL oxygenated Krebs bicarbonate solution for 1 min at 
37ºC in the presence of the phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthine 
(100 µmol/L) following a 30-min preincubation in the absence (control) or presence of 
ODQ or L-NAME at the above concentrations. Tissues were then frozen in liquid 
nitrogen, and stored at -80ºC. To determine cGMP, frozen tissues were homogenized in 
0.5 mL 0.1 mol/L HCl using a stainless steel ultraturrax (Polytron). Homogenates were 
centrifuged at 3300 g, and cGMP was measured in 300 µL supernatant by ELISA 
following acetylation (R&D Systems). Results are expressed as pmol/mg protein. The 
lower limit of detection was 0.1 pmol/mg protein. 
 
Data Analysis 
Data are given as mean±SEM or median and range. Relaxant responses are expressed as a 
percentage of the contraction to U46619. CRCs were analyzed as described46 to obtain 
pEC50 (-10logEC50) values. In experiments where no clear maximum effect (Emax) was 
reached, Emax was defined as the relaxation obtained at the highest bradykinin 
concentration tested (1 µmol/L). pEC50 values were not calculated when Emax was < 50%, 
and in such cases statistical analysis was performed under the assumption that pEC50 
equaled 6. The addition of L-NAME, ODQ, hydroxocobalamin, charybdotoxin + apamin, 
iberiotoxin + apamin, or ouabain + BaCl2 increased basal tone by 20-80%. In such cases 
the concentration of U46619 was adjusted to obtain a preconstriction corresponding with 
≈95 % of the maximal contractile response. Statistical analysis of the relaxant responses 
(pEC50 and Emax) was by t-test, once one-way ANOVA, followed by Dunnett’s post-hoc 
evaluation, had revealed that differences existed between groups. Statistical analysis of 
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the cGMP data was by Mann-Whitney U-test, because of non-normal distribution of the 
cGMP levels. P<0.05 was considered significant.  
 
Results 
 
Role of NO and H2O2 
Bradykinin relaxed preconstricted vessel segments in a concentration-dependent manner 
(pEC50 8.2±0.1, Emax 94±2%, n=32; Figure 1). Relaxation was fully prevented by Hoe140 
(n=3, data not shown), confirming that it is mediated via B2 receptors.106 L-NAME (n=8), 
ODQ (n=5) and hydroxocobalamin (n=14) shifted the bradykinin CRC to the right (pEC50 
7.4±0.4, 7.8±0.1, and 7.1±0.3, respectively), although significance was reached for L-
NAME (P<0.05) and hydroxocobalamin (P<0.01) only. When given on top of 
hydroxocobalamin, L-NAME did not induce a further rightward shift (pEC50 7.2±0.3, 
n=7). Both L-NAME and hydroxocobalamin reduced Emax (from 95±2% to 69±9% and 
60±9%, respectively; P<0.02), and a similar reduction (Emax 73±11%; P<0.01) was 
observed when the two drugs were combined. ODQ did not affect Emax (85±8%). 
Catalase, either alone (pEC50 7.7±0.5, Emax 73±13%; n=5) or on top of hydroxocobalamin 
(pEC50 6.9±0.3, Emax 50±12%; n=7), did not affect the bradykinin CRC.  
 
Role of K+ channels 
Charybdotoxin + apamin tended to decrease Emax (to 73±15%, P=NS vs. control, n=8; 
Figure 2) without affecting potency (pEC50 7.7±0.5). When given on top of 
hydroxocobalamin, charybdotoxin + apamin completely abolished bradykinin-induced 
relaxations in 6 experiments, whereas a >10-fold rightward shift was observed in 2 
experiments (difference vs. hydroxocobalamin for all 8 experiments: P<0.05). Iberiotoxin 
+ apamin did not affect the bradykinin CRC (pEC50 8.0±0.4, Emax 101±1%; n=5), nor did 
these drugs exert additional effects on top of hydroxocobalamin (pEC50 7.1±0.4, Emax 
62±15%; n=6). Moreover, in no experiment did these drugs, in combination with 
hydroxocobalamin, fully block the effects of bradykinin. Ouabain + BaCl2 decreased Emax 
to 53±14% (n=5; P<0.05) and shifted the bradykinin CRC 10-fold to the right (pEC50 
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7.1±0.5; P<0.05), but did not exert additional effects on top of hydroxocobalamin (pEC50 
6.4±0.4, Emax 26±13%; n=5).  
 
Role of EETs and gap junctions 
Clotrimazole (n=5) and sulfaphenazole (n=7) did not affect the bradykinin CRC (pEC50 
7.9±0.3 and 8.3±0.2 and Emax 89±6% and 85±10%, respectively; Figure 3), nor did 
clotrimazole exert effects on top of hydroxocobalamin (pEC50 6.7±0.6, Emax 63±8%; 
n=5). Similarly, carbenoxolone (n=5) and 18α-glycyrrhetinic acid (n=5) did not affect 
bradykinin-induced relaxation when given alone (pEC50 8.2±0.3 and 8.3±0.1 and Emax 
81±9% and 85±11%, respectively) or on top of hydroxocobalamin (pEC50 6.6±0.5 and 
6.7±0.4 and Emax 58±13% and 47±17%, respectively; n=5 for each). 
cGMP levels. Bradykinin increased microvascular cGMP from 3.9 (range 0.1-12.6) to 9.1 
(0.7-43) pmol/mg protein (n=11, P<0.01). ODQ and L-NAME reduced cGMP following 
bradykinin stimulation to 0.1 (0.1-0.5; n=5) and 0.1 (0.1-1.7; n=4) pmol/mg protein, 
respectively (P<0.001 for both). 
Figure 1.  Relaxations of HCMAs, preconstricted with U46619, to bradykinin in absence
(control) or presence of one or more of the following inhibitors: 10 µmol/L ODQ, 100 µmol/L L-
NAME, 200 µmol/L hydroxocobalamin (HC) or 1000 units/mL catalase. Data (mean±SEM; n=5-
32) are expressed as a percentage of the contraction induced by U46619. 
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Figure 2.  Relaxations of HCMAs, preconstricted with U46619, to bradykinin in absence
(control) or presence of 200 µmol/L hydroxocobalamin (HC) with one or more of the following
inhibitors: 100 nmol/L charybdotoxin (char), 100 nmol/L apamin (apa), or 100 nmol/L iberiotoxin
(iber), 1 mmol/L ouabain + 30 µmol/L BaCl2. Data (mean±SEM; n=5-32) are expressed as a
percentage of the contraction induced by U46619. 
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Figure 3. Relaxations of HCMAs, preconstricted with U46619, to bradykinin in absence (control)
or presence of 200 µmol/L hydroxocobalamin (HC) with one or more of the following inhibitors:
50 µmol/L clotrimazole, 10 µmol/L sulfaphenazole, 18α-glycyrrhetinic acid (18α-GA) or 100
µmol/L carbenoxolone. Data (mean±SEM; n=5-32) are expressed as a percentage of the
contraction induced by U46619. 
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Discussion 
 
Bradykinin-induced, B2 receptor-mediated relaxation of HCMAs in the presence of 
indomethacin depends on NO and an EDHF that is not de novo synthesized NO. Both 
pathways appear to be interchangeable, since inhibiting the EDHF pathway only (with the 
KCa channel inhibitors charybdotoxin + apamin) did not significantly shift the bradykinin 
CRC, whereas combined inhibition of the NO and EDHF pathways (with the NO 
scavenger hydroxocobalamin and charybdotoxin + apamin) resulted in full blockade of 
the bradykinin-induced effects in 6 out of 8 experiments. In the two remaining 
experiments a >10-fold rightward shift of the bradykinin CRC occurred, without an 
alteration in the maximum effect of bradykinin. The most likely explanation of this latter 
finding is incomplete scavenging of NO at the hydroxocobalamin concentration that was 
used in the present study. Its solubility did not allow us to use higher concentrations,54 
and thus, in vessels that release large amounts of NO in response to bradykinin, a 
rightward shift of the bradykinin CRC rather than complete inhibition of the bradykinin-
induced effects will occur at this concentration of hydroxocobalamin. Heterogeneity in 
bradykinin-induced NO release, as well as the possibility that EDHF replaces NO in 
vessels where endothelial B2 receptor stimulation no longer results in sufficient NO 
release, were already predicted in an earlier study investigating the effects of 
intracoronary Hoe140 application in humans.106    
In agreement with previous studies in porcine coronary arteries,54 the rightward shift of 
the bradykinin CRC in the presence of hydroxocobalamin was larger than the rightward 
shift in the presence of L-NAME. Similar data were obtained in HCMAs using the NO 
scavenger HbO and the NOS inhibitor L-NOARG.73 Taken together, these data suggest 
the release of NO from a source other than L-arginine, e.g. from NO-containing factors 
such as S-nitrosothiols. Such sources become depleted only upon repeated exposure to 
bradykinin or following prolonged NOS inhibition.54,59,107 Interestingly, the guanylyl 
cyclase inhibitor ODQ did not significantly affect the bradykinin CRC, despite the fact 
that ODQ fully prevented the 2-3-fold rise in cGMP levels following the exposure of 
HCMAs to 1 µmol/L bradykinin. This suggests that NO is capable of inducing relaxation 
through mechanisms other than the guanylyl cyclase-cGMP pathway. Since the blocking 
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effects of BaCl2 and ouabain towards bradykinin were comparable to the effect of 
hydroxocobalamin, whereas these drugs did not exert significant additional effects on top 
of hydroxocobalamin, one possibility is that NO activates KIR channels and/or Na+-K+-
ATPase directly. Evidence to support the latter is available.108,109 Direct activation of KCa 
channels by NO,72,110 seems unlikely, since neither charybdotoxin + apamin, nor 
iberiotoxin + apamin, affected the bradykinin CRC in the absence of hydroxocobalamin.  
With regard to the identity of EDHF, our data confirm the blocking effects of 
charybdotoxin + apamin, reported by Miura et al.,105 towards bradykinin in HCMAs in the 
absence of NO. However, since no significant effects were observed with the selective 
BKCa channel inhibitor iberiotoxin on top of hydroxocobalamin, the present results 
suggest that the effects of the non-selective IKCa and BKCa channel inhibitor 
charybdotoxin are due to blockade of IKCa channels rather than blockade of BKCa 
channels. Thus, the EDHF component of the bradykinin-induced relaxation in HCMAs 
involves the activation of both IKCa and SKCa channels. In endothelial cells, such 
activation results in the release of K+ in the myo-endothelial space.64 This K+ 
subsequently relaxes smooth muscle cells through activation of KIR channels and Na+-K+-
ATPase.111 Although our data are in agreement with this concept, we cannot exclude the 
possibility that the IKCa and SKCa channels are located on smooth muscle cells.  
Finally, our data do not support a role for H2O2, EETs or gap junctions in the bradykinin-
induced relaxations of HCMAs, despite previous studies in other human vessels that have 
demonstrated such a role.103,112 Apparently, the nature of EDHF differs among vessels 
from different organs, as it also varies between vessels from different species and even 
between vessels of different sizes. The lack of effect of the cytochrome P450 
epoxygenase inhibitors is in agreement with the non-significant effect of iberiotoxin, 
since EETs have been reported to exert their effects through activation of BKCa channels 
on smooth muscle cells.71 
In conclusion, bradykinin-induced relaxation in HCMAs depends on 1) the activation of 
guanylyl cyclase, KIR, and Na+/K+ ATPase by NO, and 2) IKCa and SKCa channels. The 
latter are activated by a factor other than NO. This factor is not a cytochrome P450 
epoxygenase product or H2O2, nor does it depend on gap junctions or BKCa. 
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Perspective 
Our data are the first to show that the unifying EDHF concept proposed by Busse et al.61 
also applies to human coronary arteries. As such, they form a basis for further 
investigations on the identity of EDHF, as well as on ways to interfere with EDHF in 
humans. This is of particular importance in patients with endothelial dysfunction, where 
B2 receptor-mediated vasorelaxation depends largely on EDHF.106 
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Summary 
 
We investigated whether S-nitrosothiols, in addition to NO, mediate bradykinin-induced 
vasorelaxation. Porcine coronary microarteries (PCMAs) were isolated and mounted in 
Mulvany myographs. Following preconstriction, concentration-response curves (CRCs) 
were constructed to bradykinin, the NO donors S-nitroso-N-penicillamine (SNAP) and 
diethylamine NONOate (DEA-NONOate) and the S-nitrosothiols L-S-nitrosocysteine (L-
SNC) and D-SNC. All agonists relaxed PCMAs. L-SNC was ≈5-fold more potent than D-
SNC. The guanylyl cyclase inhibitor ODQ and the NO scavenger hydroxocobalamin 
induced a larger shift of the bradykinin CRC than the NO synthase inhibitor L-NAME, 
although all three inhibitors equally suppressed bradykinin-induced cGMP responses.  
Complete blockade of bradykinin-induced relaxation was obtained with L-NAME in the 
presence of the large- and intermediate-conductance Ca2+-activated K+-channel (BKCa, 
IKCa) blocker charybdotoxin and the small-conductance Ca2+-activated K+-channel 
(SKCa) channel blocker apamin, but not in the presence of L-NAME, apamin and the 
BKCa channel blocker iberiotoxin. Inhibitors of cytochrome P450 epoxygenase, cyclo-
oxygenase, voltage-dependent K+ channels and ATP-sensitive K+ channels did not affect 
bradykinin-induced relaxation. SNAP-, DEA-NONOate- and D-SNC-induced relaxations 
were mediated entirely by the NO-guanylyl cyclase pathway. L-SNC-induced relaxations 
were partially blocked by charybdotoxin + apamin, but not by iberiotoxin + apamin, and 
this blockade was abolished following endothelium removal. ODQ, but not 
hydroxocobalamin, prevented L-SNC-induced increases in cGMP, and both drugs shifted 
the L-SNC CRC 5-10 fold to the right. L-SNC hyperpolarized intact and endothelium-
denuded coronary arteries. Our results support the concept that bradykinin-induced 
relaxation is mediated via de-novo synthesized NO and a non-NO, endothelium-derived 
hyperpolarizing factor (EDHF). S-nitrosothiols, via stereoselective activation of 
endothelial IKCa and SKCa channels, and through direct effects on smooth muscle cells, 
may function as an EDHF in porcine coronary microarteries.  
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Introduction 
 
Bradykinin relaxes coronary arteries in an endothelium-dependent manner. This effect is 
mediated via bradykinin type 2 (B2) receptors. B2 receptor activation results in NO 
synthesis by endothelial NOS, and NO relaxes vascular smooth muscle cells through 
guanylyl cyclase activation and subsequent cGMP generation.54 NOS inhibitors however 
do not completely block bradykinin-induced vasorelaxation, suggesting the existence of 
either NO-storage sites59,60 or a non-NO ‘endothelium-derived hyperpolarizing factor’ 
(EDHF).61,113  
EDHF-mediated responses in different arteries have been linked to the release of K+, the 
generation of cytochrome-P450 products from arachidonic acid (epoxyeicosatrienoic 
acids, EETs), and to the production of H2O2.62-64,66,67,111,114 The identity of EDHF and its 
contribution to to overall relaxation differs between species, between vascular beds and 
between vessels of different sizes.68 
EDHF-mediated relaxation depends on the activation of intermediate- and small-
conductance Ca2+-activated K+-channels (IKCa, SKCa).61 These channels are located on 
endothelial cells,69,70 and (as a consequence of endothelial hyperpolarization), may be 
responsible for the subsequent relaxation that is generally attributed to the release of an 
EDHF.64,65 This EDHF induces smooth muscle hyperpolarization by activating inwardly 
rectifying K+ channel (KIR) channels, Na+-K+-ATPase and/or large-conductance Ca2+-
activated K+ (BKCa) channels.61,71 With regard to the latter, it is important to note that NO 
itself is capable of inducing hyperpolarization via activation of Ca2+-activated K+ 
channels in vascular smooth muscle.72  
Bradykinin induces release of NO-containing factors (e.g., S-nitrosothiols) from cellular 
storage sites.56,59,60 Depletion of NO storage sites occurs only after repeated exposure to 
bradykinin or following prolonged inhibition of NOS.59,60 S-nitrosothiols induce 
relaxation through decomposition to NO,75 or by activating stereoselective recognition 
sites.76 These recognition sites could either be cysteine residues within Ca2+-activated K+ 
channels77 or a novel class of receptors which specifically recognize L-S-nitrosocysteine 
(L-SNC) and structurally similar S-nitrosothiols such as L-S-nitroso-β,β-
dimethylcysteine.115  
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In the present study we set out to investigate the possibility that S-nitrosothiols act as an 
EDHF in porcine coronary microarteries (PCMAs). PCMAs rather than large porcine 
coronary arteries were used, because the contribution of EDHF to vasorelaxation is larger 
in smaller vessels.54,68 We compared the relaxant effects of L-SNC to those of bradykinin 
and the NO donors S-nitroso-N-acetylpenicillamine (N-acetyl-3-(nitrosothio)-D-valine or 
SNAP) and diethylamine NONOate (DEA-NONOate), both in the absence and presence 
of an inhibitor of NOS, an inhibitor of guanylyl cyclase, and inhibitors of a wide range of 
EDHF candidates. To rule out residual NO (i.e., non-EDHF)-mediated effects as much as 
possible we also made use of the NO scavenger hydroxocobalamin. Guanylyl cyclase 
activation by NO or NO-containing factors was quantified by measuring cGMP 
generation. To verify the stereoselectivity of L-SNC-induced effects, parallel experiments 
were performed with D-S-nitrosocysteine (D-SNC). Finally, electrophysiological 
measurements were performed in intact and endothelium-denuded porcine coronary 
arteries to verify direct hyperpolarization by bradykinin and L-SNC. 
 
Methods 
 
Drugs 
Bradykinin, SNAP, DEA-NONOate, L-cysteine, D-cysteine, NaNO2, 9,11-dideoxy-
11α,9α-epoxy-methano-prostaglandin F2α (U46619), Nω-nitro-L-arginine methyl ester 
HCl (L-NAME), Nω-nitro-L-arginine (L-NA), 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-
one (ODQ), hydroxocobalamin, indomethacin, diclofenac, glibenclamide, 4-
aminopyridine, charybdotoxin, apamin, iberiotoxin, ouabain, BaCl2, sulfaphenazole, 
miconazole and 3-isobutyl-1-methyl-xanthine were from Sigma-Aldrich (Zwijndrecht, 
The Netherlands). D-Arg[Hyp3,Thi5,D-Tic7,Oic8]-bradykinin (Hoe140) was a kind gift of 
Dr. W. Linz, Hoechst, Frankfurt, Germany. Indomethacin, glibenclamide, ouabain and 
ODQ were dissolved in dimethylsulphoxide. Sulfaphenazole and miconazole were 
dissolved in ethanol. Hydroxocobalamin was dissolved in methanol. All other chemicals 
were dissolved in water. 
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Tissue collection 
Pig hearts (n=123) were collected at the local slaughterhouse. Epicardial arteries 
(diameter ≈1.5 mm) and tertiary branches of the left anterior descending coronary artery 
(PCMAs; diameter 337±8.4 µm) were removed and either used directly or stored 
overnight in cold, oxygenated Krebs bicarbonate solution of the following composition 
(mM): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 
8.3; pH 7.4.  
 
Organ bath studies 
PCMAs were cut into segments of ≈2 mm length and mounted in microvascular 
myographs (J.P. Trading) with separated 6-ml organ baths containing Krebs bicarbonate 
solution aerated with 95% O2/5% CO2 and maintained at 37°C. Changes in contractile 
force were recorded with a Harvard isometric transducer. Following a 30-min 
stabilization period, the internal diameter was set to a tension equivalent to 0.9 times the 
estimated diameter at 100 mm Hg effective transmural pressure.89 
The normalised vessel segments were exposed to 30 mM KCl twice. In some vessels, the 
endothelium was removed by gently rubbing a hair through the lumen of the mounted 
artery. Endothelial integrity or removal was verified by observing relaxation (or lack 
thereof) to 10 nM substance P after preconstriction with 10 nM of the thromboxane-A2 
analogue U46619. The maximal contractile response to KCl was determined by exposing 
the tissue to 100 mM KCl. Thereafter, vessels were allowed to equilibrate in fresh organ 
bath fluid for 30 min in the absence or presence of one or more of the following 
inhibitors: the NOS inhibitor L-NAME (100 µM), the NO scavenger hydroxocobalamin 
(200 µM), the guanylyl cyclase inhibitor ODQ (10 µM), the COX inhibitor indomethacin 
(10 µM), the IKCa + BKCa channel inhibitor charybdotoxin (100 nM), the SKCa channel 
inhibitor apamin (100 nM), the BKCa channel inhibitor iberiotoxin (100 nM), the voltage-
dependent K+ channel (Kv) inhibitor 4-aminopyridine (5 mM), the ATP-sensitive K+ 
channel (KATP) inhibitor glibenclamide (1 µM), the KIR inhibitor BaCl2 (30 µM), the Na+-
K+-ATPase inhibitor ouabain (0.5 mM), the cytochrome P450 epoxygenase inhibitors 
sulfaphenazole or miconazole (10 µM) or the B2 receptor antagonist Hoe140 (1 µM). 
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Vessels were then preconstricted with U46619, and concentration-response curves 
(CRCs) were constructed to bradykinin, SNAP, DEA-NONOate, L-SNC or D-SNC. L-
SNC and D-SNC were prepared immediately prior to the experiment and stored in the 
dark below 0°C. In short, 50 µL of a 0.2 M solution of L-cysteine, D-cysteine was mixed 
with 50 µL 0.2 M NaNO2. The subsequent addition of 10 µL 1 M HCl resulted in a stable 
0.1 M solution (pH ≈ 5) of the respective SNC isomers.76 Preliminary studies with 
NaNO2, L-cysteine and D-cysteine (n=3 each) revealed that, separately, these drugs did 
not exert relaxant effects in preconstricted PCMAs (data not shown).  
 
Cyclic GMP measurement 
To study bradykinin- and L-SNC induced cGMP production, vessel segments (5-10 mg) 
were exposed to bradykinin (1 µM) or L-SNC (10 or 100 µM) in 10 ml oxygenated Krebs 
bicarbonate solution for 1 min at 37ºC in the presence of the phosphodiesterase inhibitor 
3-isobutyl-1-methyl-xanthine (100 µM), following a 30-min preincubation in the absence 
(control) or presence of hydroxocobalamin, ODQ, Hoe140 and/or L-NAME at the above 
concentrations. Tissues were subsequently frozen in liquid nitrogen, and stored at -80ºC. 
To determine cGMP, frozen tissues were homogenized in 0.5 mL 0.1 M HCl using a 
stainless steel ultraturrax (Polytron). Homogenates were centrifuged at 3300 g, and 
cGMP was measured in 300 µL supernatant by ELISA following acetylation (R&D 
Systems). Experiments were performed in quadruplicate, and results are expressed as 
pmol mg-1 protein. The lower limit of detection was 0.1 pmol mg-1 protein. 
 
Electrophysiological measurements 
Freshly isolated epicardial artery segments (≈40 mm length) were excised, slit and 
mounted in heated (37°C) chambers and maintained in modified Tyrode’s solution (in 
mM: NaCl 132, KCl 4, CaCl2 1.6, MgCl2 1.2, NaH2PO4 0.36, NaHCO3 23.8, Ca2+-EDTA 
0.05, glucose 10; gassed with 20% O2/5% CO2/75 % N2, pH 7.4) containing the NOS 
inhibitor L-NA (300 µM), the COX inhibitor diclofenac (10 µM), and U46619 (1 µM) to 
mimic conditions in the organ chamber experiments as closely as possible.
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Both endothelium intact and endothelium-denuded segments were used. Smooth muscle 
membrane potential was recorded by impaling cells through the intima as described.63 
Bradykinin (100 nM) and L-SNC (50 µM) were applied as bolus injections into the bath.  
 
Data analysis 
Data are given as mean±s.e.mean. Contractile responses are expressed as a percentage of 
the contraction to U46619. CRCs were analysed as described using the logistic function 
described by de Lean et al.116 to obtain pEC50 (-10logEC50) values (Table 1). L-NAME, 
ODQ, hydroxocobalamin and/or ouabain+BaCl2 increased basal tone by 10-40%, 
whereas 4-aminopyridine increased basal tone by 80%. In such cases the concentration of 
U46619 (range 10-30 nM) was adjusted to obtain a preconstriction corresponding to 
≈95% of the maximal contractile response in all vessels. Statistical analysis was by paired 
t-test, once one-way ANOVA, followed by Dunnett’s post-hoc evaluation, had revealed 
that differences existed between groups. P<0.05 was considered significant.  
 
Results 
 
Mechanism of Bradykinin-Induced Relaxation 
Bradykinin relaxed preconstricted vessel segments in a concentration-dependent manner 
(pEC50 = 8.2±0.1, n=45; Figure 1). Bradykinin-induced relaxations were unaffected by 
indomethacin and abrogated by Hoe140. L-NAME shifted the bradykinin CRC ≈5-fold to 
the right, whereas ODQ and hydroxocobalamin induced a ≈10-fold rightward shift (see 
Table 1 for pEC50 values). Apamin, iberiotoxin and charybdotoxin, separately or in 
combination, did not significantly affect the bradykinin CRC (Figure 2, Table 1), nor did 
ouabain + BaCl2 (Figure 1, Table 1). 
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Figure 1. Relaxations of PCMAs, preconstricted with U46619, to bradykinin in absence (control;
A, B) or presence of of 100 µM L-NAME (C, D) with one or more of the following inhibitors: 1 µM
Hoe140, 10 µM ODQ, 10 µM indomethacin, 100 µM L-NAME, 200 µM hydroxocobalamin (HC),
0.5 mM ouabain, 30 µM BaCl2, 1 µM glibenclamide, 5 mM 4-aminopyridine, 10 µM miconazole
or 10 µM sulfaphenazole. Data (mean±s.e.mean; n=5-45) are expressed as a percentage of the
contraction induced by U46619. 
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In the presence of L-NAME, apamin and charybdotoxin, when given separately, did not 
affect the bradykinin CRC (pEC50s 7.8±0.3 and 8.2±0.2, respectively, n=6 for each; 
Figure 2), nor did glibenclamide, 4-aminopyridine, sulfaphenazole and miconazole 
(pEC50s 7.8±0.5, 8.0±0.3, 7.8±0.4 and 7.9±0.6 , respectively, n=5 for each; Figure 1). In 
contrast, when given in addition to L-NAME, charybdotoxin + apamin fully blocked the 
bradykinin-induced responses (Figure 2, n=5), whereas hydroxocobalamin (n=5) and 
ouabain + BaCl2 (n=5) shifted the bradykinin CRC >100-fold (P<0.01; Figure 1) to the 
right. Iberiotoxin, without (n=6) or with (n=6) apamin, reduced the maximum effect of 
bradykinin in the presence of L-NAME (P<0.01; Figure 2), without altering its pEC50 
(7.8±0.5 and 8.1±0.2, respectively).  
Thus, NO and/or NO-containing factors as well as Ca2+-activated K+-channels (BKCa, 
IKCa and SKCa), KIR channels, and Na+-K+-ATPase are involved in the bradykinin-
induced relaxation, and the NO-induced effects are mediated, at least in part, via 
activation of guanylyl cyclase. No evidence for a role of Kv channels, KATP channels, 
COX products, or cytochrome P450 epoxygenase products was obtained.  
 
Mechanism of NO-Induced Relaxation 
SNAP and DEA-NONOate relaxed preconstricted coronary microvessels in a 
concentration-dependent manner (Figures 3 and 4; Table 1). Both hydroxocobalamin and 
ODQ shifted the SNAP and DEA-NONOate-induced CRC to the right and, in 
combination, completely blocked SNAP-induced relaxation. Charybdotoxin + apamin, 
either as combination or together with hydroxocobalamin or ODQ, did not elicit a 
rightward shift in the SNAP or DEA-NONOate CRC.  
Thus, the relaxation induced by exogenous NO depends entirely on activation of guanylyl 
cyclase, and does not involve Ca2+-activated K+-channels. 
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Figure 2.  Relaxations of PCMAs, preconstricted with U46619, to bradykinin in absence (control;
A, B) or presence of 100 µM L-NAME (C, D) with one or more of the following inhibitors: 100 nM
charybdotoxin (char), 100 nM apamin (apa), or 100 nM iberiotoxin (iber). Data (mean±s.e.mean;
n=5-45) are expressed as a percentage of the contraction induced by U46619. 
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Figure 3. Relaxations of PCMAs, preconstricted with U46619, to SNAP in the absence (control)
or presence of one or more of the following inhibitors: 10 µM ODQ, 200 µM hydroxocobalamin
(HC), 100 nM charybdotoxin (char) or 100 nM apamin (apa). Data (mean±s.e.mean; n=5-14) are
expressed as a percentage of the contraction induced by U46619. 
 
5678910
-20
0
20
40
60
80
100
control
ODQ
HC
char+apa
- log [DEA-NONOate] (M)
%
 r
el
ax
at
io
n
Figure 4. Relaxations of PCMAs,
preconstricted with U46619, to DEA-
NONOate in the absence (control) or
presence of one or more of the following
inhibitors: 10 µM ODQ, 200 µM
hydroxocobalamin (HC), 100 nM
charybdotoxin (char) or 100 nM apamin
(apa). Data (mean±s.e.mean; n=4) are
expressed as a percentage of the
contraction induced by U46619. 
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Mechanism of S-nitrosothiol-induced relaxation  
L-SNC and D-SNC relaxed preconstricted PCMAs in a concentration-dependent manner. 
L-SNC was 5 times more potent than D-SNC (P<0.05; Figure 5, Table 1). ODQ and 
hydroxocobalamin shifted the CRCs of both L-SNC and D-SNC 5-10-fold to the right 
(P=NS for the difference in rightward shift between L-SNC and D-SNC) and, when 
combined, caused a further rightward shift (Table 1).  
 
Charybdotoxin + apamin shifted the L-SNC CRC, but not the D-SNC CRC, 5-10 fold to 
the right (Figure 6, Table 1). Endothelium-denudation shifted the L-SNC CRC 5-10 fold 
to the left, and abolished the rightward shift induced by charybdotoxin + apamin (Figure 
6, Table 1). Charybdotoxin + apamin did not have additional effects on top of ODQ, 
hydroxocobalamin (Table 1) or ODQ + hydroxocobalamin (Figures 5 and 6, Table 1) 
with either L-SNC or D-SNC.  
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Figure 5. Relaxations of PCMAs, preconstricted with U46619, to L-SNC or D-SNC in the
absence (control) or presence of 10 µM ODQ and/or 200 µM hydroxocobalamin (HC). Data
(mean±s.e.mean; n=4-18) are expressed as a percentage of the contraction induced by
U46619. 
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Figure 6. Relaxations of PCMAs without (A) or with (B, C) endothelium, preconstricted with
U46619, to L-SNC or D-SNC in the absence (control) or presence of one or more of the
following inhibitors: 10 µM ODQ, 200 µM hydroxocobalamin (HC), 100 nM charybdotoxin (char)
or 100 nM apamin (apa). Data (mean±s.e.mean; n=4-18) are expressed as a percentage of the
contraction induced by U46619. 
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Figure 7. Relaxations of PCMAs, preconstricted with U46619, to L-SNC in the absence (control)
or presence of one or more of the following inhibitors: 100 nM iberiotoxin (iber), 100 nM apamin
(apa), 5 mM 4-aminopyridine (4-AP), 100 µM L-NAME, 1 µM glibenclamide, 0.5 mM ouabain or
30 µM BaCl2. Data (mean±s.e.mean; n=4-9) are expressed as a percentage of the contraction
induced by U46619. 
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Glibenclamide, 4-aminopyridine, L-NAME, apamin, iberiotoxin, and iberiotoxin + 
apamin did not affect the L-SNC CRC (Figure 7, Table 1).  
Ouabain + BaCl2 shifted the L-SNC CRC 5-fold to the right (Figure 7, Table 1) but did 
not exert an additional effect on top of hydroxocobalamin (pEC50 5.9±0.2,  n=4; Figures 5 
and 7). 
Thus, S-nitrosothiol-induced relaxation occurs in a stereoselective manner, and is 
mediated via activation of guanylyl cyclase, endothelial IKCa and SKCa channels, KIR 
channels and the Na+-K+-ATPase. Neither NOS, Kv channels, KATP channels, nor BKCa 
channels appear to mediate this response. 
 
Cyclic GMP 
Baseline cGMP levels were 9.4±2.7 pmol mg-1 protein (n=16). Bradykinin increased the 
microvascular cGMP levels 4-5 fold (Figure 8; P<0.05 vs. control). Hoe140 largely 
prevented this increase, whereas L-NAME, hydroxocobalamin and ODQ reduced the 
microvascular cGMP content following bradykinin stimulation to levels below baseline. 
The combination of hydroxocobalamin and L-NAME did not further decrease cGMP 
levels. L-SNC increased cGMP >5-fold (P<0.05 vs control). ODQ fully prevented the 
increase induced by 10 µM L-SNC, and a similar tendency was observed for 
hydroxocobalamin (P=NS). ODQ did not fully prevent the increase induced by by 100 
µM L-SNC. 
 
Electrophysiological measurements 
Both bradykinin (n=6) and L-SNC (n=6) hyperpolarized vascular smooth muscle cells 
(P<0.01) in porcine coronary arteries (Figure 9). The effect of L-SNC was not affected by 
the removal of the endothelium (n=5). 
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Figure 8. Cyclic GMP levels (expressed as % of baseline) in PCMAs after 1 min exposure to (A)
bradykinin (1 µM) or (B) L-SNC (10 µM or 100 µM) under control conditions (no blocker) and in
the presence of 10 µM ODQ, 200 µM hydroxocobalamin (HC), 1 µM Hoe140 and/or 100 µM L-
NAME. Data are mean±s.e.mean (n=3-10). # P<0.05 vs. control, * P<0.05 vs. no blocker. 
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Figure 9. Hyperpolarization of smooth
muscle cells by 100 nM bradykinin and
50 µM L-SNC in porcine coronary
arteries with or without endothelium. A,
resting membrane potential (RMP). B,
change in membrane potential.
Experiments were performed in the
presence of 300 µM L-NA, 10 µM
diclofenac and 1 µM U46619. Data are
mean±s.e.mean of 5-6 separate
experiments; * P<0.01 vs. control.
U46619 did not significantly affect RMP
(–44.5±1.2 mV vs. –42.7± 1.7 mV, n=6),
and in parallel experiments, using arterial
rings from the same pig and following
preconstriction with the same U46619
concentration (1 µM), 100 nM bradykinin
relaxed the arteries by 89±9% (n=6).  
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Discussion 
 
The present study shows that B2 receptor-mediated vasodilation in porcine coronary 
microarteries involves the NOS/NO/guanylyl cyclase/cGMP pathway and Ca2+-activated 
K+-channels, but not COX products or KATP channels. This is in full agreement with the 
concept that both NO and an EDHF that is not de novo synthesized NO determine 
bradykinin-induced relaxation. The two pathways appear to be interchangeable, since 
blocking each pathway separately (with L-NAME and charybdotoxin + apamin, 
respectively) only marginally affected bradykinin-mediated relaxation, whereas blocking 
both pathways together abrogated the effects of bradykinin. The modest effect of 
blocking NOS in the present study opposes earlier data in large porcine coronary arteries, 
where L-NAME alone induced a ≈10-fold rightward shift of the bradykinin CRC.54 
Apparently, as has been suggested before, de novo synthesized NO is of greater 
importance in large arteries, and the contribution of EDHF is larger in microarteries.68  
The BKCa channel inhibitor iberiotoxin, with or without the SKCa channel inhibitor 
apamin, reduced the maximum effect but not the potency of bradykinin in the presence of 
L-NAME. This finding, combined with the lack of effect of the Kv channel inhibitor 4-
aminopyridine, suggests that the complete inhibition of bradykinin-induced relaxation 
obtained with charybdotoxin (a non-selective inhibitor of BKCa, IKCa and Kv channels) in 
the presence of apamin and L-NAME can be attributed to the blockade of all three types 
of KCa channels.  
BKCa channels are located on vascular smooth muscle cells.71 Although endothelial EETs 
are believed to activate these channels,61,63,64,71,117-119 the lack of effect of the cytochrome 
P450 epoxygenase inhibitors miconazole and sulfaphenazole excludes this possibility in 
our experimental setup.  
IKCa and SKCa channels are expressed in endothelial cells 69,70,69,70 and their activation 
results in endothelial hyperpolarization and the accumulation of K+ in the myo-
endothelial space. This K+ is believed to subsequently hyperpolarize vascular smooth 
muscle cells by activating KIR channels and/or the Na+-K+-ATPase.61,64,65 The inhibitory 
effect of BaCl2 and ouabain towards bradykinin in the presence of L-NAME confirms 
this concept in PCMAs.  
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S-Nitrosothiols as EDHF? 
We propose that NO-containing/releasing factors, S-nitrosothiols in particular, act as an 
EDHF in PCMAs. The contribution of such factors is supported by our observations that 
the guanylyl cyclase inhibitor ODQ and the NO scavenger hydroxocobalamin inhibited 
the bradykinin-induced effects to a much greater degree than L-NAME, and that, in 
combination, L-NAME + hydroxocobalamin almost completely prevented bradykinin-
induced relaxations. Since S-nitrosothiol-induced relaxations occur through activation of 
stereoselective recognition sites and/or via their decomposition to NO,76,120 we used both 
L-SNC and D-SNC to verify this proposal.  
L-SNC was ≈5 times more potent than D-SNC. This difference disappeared in the 
presence of charybdotoxin + apamin (but not in the presence of iberiotoxin with or 
without apamin), suggesting that L-SNC, but not D-SNC, hyperpolarizes endothelial cells 
via IKCa and SKCa channel activation. The comparable rightward shift of the L-SNC CRC 
in the presence of ouabain + BaCl2 and charybdotoxin + apamin is in agreement with the 
concept that such hyperpolarization results in endothelial K+ release and subsequent 
smooth muscle cell hyperpolarization. In further support of this hypothesis, endothelium-
denudation abolished the effect of charybdotoxin + apamin towards L-SNC, and L-SNC 
reduced the membrane potential of smooth muscle cells in intact porcine coronary 
arteries.  
Unexpectedly however, the removal of the endothelium potentiated L-SNC 5-10 fold. 
This suggests that L-SNC, like other endothelium-dependent vasodilators, not only 
hyperpolarizes endothelial cells, but also induces the release of an endothelium-derived 
contractile factor.121 Alternatively, endothelial denudation might uncover direct L-SNC-
induced effects on smooth muscle cells, as evidenced by the fact that L-SNC also 
hyperpolarized endothelium-denuded coronary arteries. One such direct effect is BKCa 
channel activation via S-nitrosylation of cysteine residues.77 However, the lack of effect 
of charybdotoxin + apamin towards L-SNC in endothelium-denuded vessels does not 
support this concept in PCMAs.  
Taken together, the relaxant effects of L-SNC, like those of bradykinin, involve KCa 
channels, and they occur, at least in part, in a stereoselective manner.   
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The greater potency of L-SNC versus D-SNC is in agreement with previous in vivo 
studies,76,120 and may indicate the existence of binding sites that specifically recognize L-
SNC and structurally related S-nitrosothiols. These binding sites may either be novel 
receptors or ‘nitrosation motifs’ in functional proteins such as receptors and ion channels. 
77,115,122,123 
 
NO Release from S-Nitrosothiols? 
The effects of L-SNC, at the concentrations used in the present study, are unlikely to be 
due entirely to its decomposition to NO, nor do they involve de novo NO generation by 
NOS. First, NO did not activate Ca2+-activated K+ channels in PCMAs, because the 
dilatory effects of the NO donors SNAP and DEA-NONOate were unaffected by 
charybdotoxin and apamin. Second, L-NAME did not affect L-SNC-mediated responses. 
Third, detectable NO production has been reported to occur at S-nitrosothiol 
concentrations above 100 µM only,124 i.e., at concentrations that are >100 times above the 
EC50 value of L-SNC in the present study. Fourth, the ODQ, but not hydroxocobalamin, 
fully prevented the L-SNC-induced increases in cGMP. This suggests direct, NO-
independent, activation of guanylyl cyclase by L-SNC, in agreement with a previous 
study in cultured vascular smooth muscle cells.125 Alternatively, the concentration of 
hydroxocobalamin used in the present study may have been too low to scavenge all NO 
generated following L-SNC application.126  
Taken together, the following mechanisms may underlie L-SNC-induced vasorelaxation: 
direct activation of endothelial IKCa and SKCa channels, direct activation of guanylyl 
cyclase in smooth muscle cells, and decomposition to NO. Simultaneous inhibition of all 
mechanisms (with charybdotoxin + apamin, ODQ and hydroxocobalamin, respectively) 
did not fully prevent the relaxations induced by the highest concentration of L-SNC (100 
µM). This could relate to the inability of hydroxocobalamin to scavenge all NO126 and/or 
the competitive inhibition of guanylyl cyclase by ODQ,127 allowing full blockade of the 
cGMP increases and relaxations induced by 10 µM L-SNC, but not of those induced by a 
tenfold higher L-SNC concentration (Figures 6 and 8). 
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Release of S-nitrosothiols?  
Finally, despite the fact that L-SNC is capable of exerting EDHF-like effects, direct 
evidence demonstrating that L-SNC (or a related compound) mediates bradykinin-
induced, EDHF-dependent relaxation is currently lacking. Previous studies support the 
existence of preformed pools of NO-containing factors (such as S-nitrosothiols) in 
endothelial and vascular smooth muscle cells.54,59,107,128 These pools become depleted after 
repeated exposure to endothelium-dependent agonists such as acetylcholine and 
bradykinin, following prolonged NOS inhibition, or after exposure to UV.54,59,107 
We did not measure S-nitrosothiol release following bradykinin stimulation in the present 
study. Such release may occur in a specific compartment (e.g., the myo-endothelial space, 
gap junctions, intra-endothelial) that does not allow easy detection. Moreover, since it 
depends on preformed pools, it cannot be monitored by measuring the vascular 
S-nitrosothiol content following bradykinin stimulation. Similar difficulties exist with 
regard to EETs,71,118 and it has therefore been proposed that these cytochrome-P450 
products contribute to the activation of endothelial K+ channels as second messengers,61 
rather than being released from endothelial cells in large amounts.  
 
Clinical perspective 
S-nitrosylated proteins, the most abundant of which is albumin, are present in micromolar 
concentrations in normal subjects.122 They are thought to serve both as a source and a sink 
of NO, thereby buffering the concentration of free NO. A recent in vivo study showed 
that S-nitrosothiols induce dilator responses in human conduit and resistance arteries that 
are comparable with those of bradykinin and acetylcholine,129 and it has therefore been 
suggested130 that S-nitrosothiols provide a new pharmacological route for delivering NO 
regionally. Our data extend these findings, by implying not only that S-nitrosothiols may 
act by inducing hyperpolarization in microarteries (i.e., exert NO-independent effects), 
but also by showing that their effects occur in a stereoselective manner.
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Summary 
 
Bradykinin-induced, endothelium-derived hyperpolarizing factor (EDHF)-mediated 
responses depend on Ca2+-dependent K+-channels (KCa) of small (SKCa) and intermediate 
(IKCa) conductance, inwardly rectifying K+ (KIR) channels and/or Na+-K+-ATPase. Here 
we investigated in porcine coronary arteries (PCAs) whether S-nitrosothiols can act as 
EDHF. Preconstricted PCAs were exposed to bradykinin, the NO donor S-nitroso-N-
penicillamine (SNAP), or the S-nitrosothiols L-S-nitrosocysteine (L-SNC), D-SNC and 
L-S-nitrosoglutathione (L-SNG), with or without KCl, the NO scavenger 
hydroxocobalamin, the S-nitrosothiol-depleting agent p-hydroxymercurobenzoic acid 
(PHMBA) and/or inhibitors of NO synthase (L-NAME), guanylyl cyclase (ODQ), SKCa 
channels (apamin), KCa channels of large conductance (BKCa) (iberiotoxin), IKCa + BKCa 
channels (charybdotoxin), KIR channels (BaCl2) or Na+-K+-ATPase (ouabain). All 
agonists concentration-dependently relaxed PCAs. L-NAME, charybdotoxin + apamin, 
KCl, and ouabain shifted the bradykinin concentration-response curve (CRC) ≈10-fold to 
the right. BaCl2 did not exert additional effects on top of ouabain. Full blockade of 
bradykinin was obtained when combining L-NAME with charybdotoxin + apamin, KCl 
or ouabain + BaCl2. PHMBA reduced the maximum effect of bradykinin. Iberiotoxin + 
apamin, alone or on top of L-NAME, did not affect bradykinin, SNAP or L-SNC. ODQ 
and hydroxocobalamin shifted the SNAP, L-SNC, D-SNC, and L-SNG CRCs ≈10-fold to 
the right, and, in combination, fully blocked SNAP-induced effects. Charybdotoxin + 
apamin shifted the L-SNC and L-SNG CRCs, but not the D-SNC or SNAP CRCs, ≈5-
fold to the right. KCl and ouabain (but not BaCl2) shifted the SNAP, L-SNC and L-SNG 
CRCs 5-10 fold to the right. In conclusion, L-S-nitrosothiols activate SKCa + IKCa 
channels in a stereoselective manner, whereas NO activates Na+-K+-ATPase. Since S-
nitrosothiols decompose to NO, stored L-S-nitrosothiols may mediate bradykinin-
induced, EDHF-dependent relaxation.  
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Introduction 
 
Bradykinin-induced relaxation of coronary arteries is thought to depend on NO 
synthesized de novo by endothelial NO synthase (NOS) as well as a non-NO 
endothelium-derived hyperpolarizing factor (EDHF). At present, there is no clear 
consensus on the identity of EDHF or the exact mechanism by which EDHF relaxes 
smooth muscle cells. According to a recent review,61 EDHF release from endothelial cells 
depends on the activation of endothelial intermediate-conductance and small-conductance 
Ca2+-dependent K+-channels (IKCa, SKCa).64,65,69,70,131 Subsequently, EDHF is assumed to 
hyperpolarize smooth muscle cells through activation of inwardly rectifying K+ channel 
(KIR) channels, Na+-K+-ATPase and/or large-conductance Ca2+-dependent K+ (BKCa) 
channels.61,64,71,132 With regard to the latter, it is important to note that NO itself is capable 
of inducing hyperpolarization via activation of Ca2+-dependent K+ channels and Na+-K+-
ATPase.72,108,109 EDHF candidates include prostacyclin, K+, and cytochrome-P450 
products of arachidonic acid (epoxyeicosatrienoic acids, EETs).61,63-65,71  
In previous studies on bradykinin-induced relaxation of porcine coronary arteries (PCAs), 
we and others were unable to demonstrate a role for either prostacyclin or EETs, both in 
the absence and presence of the NOS inhibitor Nω-nitro-L-arginine methyl ester HCl (L-
NAME).54,133,134 Interestingly, the NO scavenger hydroxocobalamin blocked the 
bradykinin-induced relaxation of PCAs to a greater degree than L-NAME.54 Similar 
observations were made in human coronary arteries, where it was simultaneously 
observed that increasing the concentration of the NOS inhibitor did not yield additional 
effects.57,73 Taken together, these data support the release of NO or an NO-containing 
factor from a source that does not depend on the acute conversion of L-arginine by NOS. 
Repeated bradykinin exposure rapidly depletes such ‘NO pools’, independently of 
bradykinin type 2 receptor desensitisation.54,56,59,60 NO-containing factors are also thought 
to mediate light-induced photorelaxation of vascular smooth muscle cells.74,135 
Nitrosothiol-depleting agents reduce photorelaxation responses,74 and S-nitrosothiols have 
therefore been proposed to mediate this phenomenon.  
Similarly, S-nitrosothiols might be the tissue source of non-de novo synthesized NO. S-
nitrosothiols induce relaxation not only through their decomposition to NO,75 but also by 
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activating stereoselective recognition sites.76 Recently, the cysteine residues within the α 
subunit of the BKCa channel were identified as a S-nitrosothiol binding site.77  
It was the aim of the present study to investigate whether S-nitrosothiols mediate the 
bradykinin-induced, EDHF-dependent relaxation in PCAs. First, we verified the exact 
mechanism of the bradykinin-induced, EDHF-mediated responses in PCAs, and we 
studied the effects of nitrosothiol-depleting agents on bradykinin-induced relaxation with 
or without L-NAME. Second, we ruled out the possibility that NO mediates EDHF-like 
responses, using the NO donor S-nitroso-N-penicillamine (SNAP). Third, we investigated 
the pathways involved in the relaxant effects of S-nitrosothiols, as well as the 
stereoselectivity of their effects, using the S-nitrosothiols L-S-nitrosocysteine (L-SNC), 
D-SNC and L-S-nitrosoglutathione (L-SNG). 
 
Methods 
 
Tissue collection 
Coronary arteries were obtained from 92 slaughterhouse pigs. The arteries were removed 
after the heart had been brought to the laboratory in cold, oxygenated Krebs bicarbonate 
solution of the following composition (mmol/l): NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 
1.2, KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 7.4. Vessels were stored in cold, 
oxygenated Krebs bicarbonate solution for 12 or 36 hours. They were then cut into 
segments of approximately 4 mm length, suspended on stainless steel hooks in 15 ml-
organ baths containing Krebs bicarbonate solution, aerated with 95% O2 / 5% CO2, and 
maintained at 37°C. In some segments, the tips of a pair of watchmakers forceps had 
been inserted into the lumen to remove the endothelium by gently rolling the ring back 
and forth over saline-loaded filter paper. 
 
Organ bath studies 
All vessel segments were allowed to equilibrate for at least 30 min and the organ bath 
fluid was refreshed every 15 min during this period. Changes in tissue contractile force 
were recorded with a Harvard isometric transducer (South Natick, MA, USA). The vessel 
segments, stretched to a stable force of about 15 mN, were exposed to 30 mmol/l KCl 
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twice. The functional integrity of the endothelium (or its absence) was verified by 
observing relaxation to 1 nmol/l substance P after preconstriction with 1 µmol/l U46619. 
Subsequently, the tissue was exposed to 100 mmol/l KCl to determine the maximal 
contractile response to KCl. The segments were then allowed to equilibrate in fresh organ 
bath fluid for 30 min in the absence or presence of one or more of the following 
inhibitors: the NOS inhibitors L-NAME (100 or 300 µmol/l) and Nω-nitro-L-arginine (L-
NOARG) (100 µmol/l), the NO scavenger hydroxocobalamin (200 µmol/l), the guanylyl 
cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ, 10 µmol/l), the S-
nitrosothiol-depleting agents ethacrynic acid (50 µmol/l) and p-hydroxymercurobenzoic 
acid (PHMBA, 10 µmol/l), the IKCa + BKCa channel inhibitor charybdotoxin (100 
nmol/l), the SKCa channel inhibitor apamin (100 nmol/l), the BKCa channel inhibitors 
iberiotoxin (100 nmol/l) and tetraethylammonium (1 mmol/l), the two-pore domain K+ 
channel (TASK-1) inhibitor ZnCl2 (200 µmol/l),136 the KIR inhibitor BaCl2 (30 µmol/l), 
the Na+-K+-ATPase inhibitor ouabain (1 mmol/l) or KCl (20 mmol/l). Vessels were then 
preconstricted with U46619, and concentration-response curves (CRCs) were constructed 
to bradykinin, SNAP, L-SNC, D-SNC, L-SNG or KCl. In the experiments evaluating the 
effect of relaxant effects of KCl, KCl in the Krebs buffer was replaced by NaCl. L-SNC, 
D-SNC and L-SNG were prepared immediately prior to the experiment and stored in the 
dark on ice. In short, 50 µl of a 0.2 mol/l solution of L-cysteine, D-cysteine or L-
glutathione was mixed with 50 µl 0.2 mol/l NaNO2. The subsequent addition of 10 µl 1 
mol/l HCl resulted in a stable 0.1 mol/l solution of the respective isomers. Preliminary 
studies with NaNO2, L-cysteine, D-cysteine and L-glutathione (n=3-6 each) revealed that, 
separately, these drugs did not exert relaxant effects in preconstricted PCAs (data not 
shown).  
 
Data analysis 
Data are given as mean±SEM. No differences were observed between PCAs that had 
been stored for 12 hours or 36 hours, and data from all vessels were therefore combined. 
Relaxant responses are expressed as a percentage of the contraction to U46619. CRCs 
were analyzed as described using the logistic function described46 to obtain pEC50 (-
10logEC50) values. L-NAME, ODQ, hydroxocobalamin, BaCl2, ouabain and KCl 
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increased basal tone to 10-15% of the maximum contractile response when given 
separately, and to 15-40% of the maximum contractile response when given in 
combination. U46619-induced preconstrictions were corrected for this increase in 
baseline. Statistical analysis versus control was by one-way ANOVA, followed by 
Dunnett’s post-hoc evaluation. P<0.05 was considered significant.  
 
Results 
 
Bradykinin-induced relaxation 
Bradykinin relaxed preconstricted vessel segments in a concentration-dependent manner 
(pEC50=7.8±0.1, n=21; Figure 1). L-NAME (100 µmol/l) shifted the bradykinin CRC 
≈10-fold to the right (pEC50=7.1±0.1, n=20; P<0.01). Increasing the L-NAME 
concentration threefold (n=6), or using the NOS inhibitor L-NOARG (n=6) yielded 
similar results (Figure 2), indicating that NOS inhibition was maximal at a concentration 
of 100 µmol/l L-NAME. Comparable rightward shifts were obtained with KCl 
(pEC50=6.6±0.3, n=7; P=0.10), charybdotoxin + apamin (pEC50=6.5±0.1, n=6; P<0.01) 
and ouabain + BaCl2 (pEC50=6.3±0.4, n=8; P<0.01), but not with iberiotoxin + apamin 
(pEC50=7.4±0.1, n=8).  
Complete blockade of the bradykinin-induced effects was obtained when combining L-
NAME with either KCl (n=5), charybdotoxin + apamin (n=6), or ouabain + BaCl2 (n=8). 
In contrast, iberiotoxin + apamin did not have an additional effect on top of L-NAME 
(n=10).  
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Figure 1. Relaxations of PCAs, preconstricted with U46619, to bradykinin in the absence
(control) or presence of 100 µmol/l L-NAME and/or 20 mmol/l KCl, 100 nmol/l charybdotoxin
(char) + 100 nmol/l apamin (apa), 100 nmol/l iberiotoxin (iber) + 100 nmol/l apamin, or 1 mmol/l
ouabain (ouab) + 30 µmol/l BaCl2 (Ba2+). Data (mean±SEM of 5-21 experiments) are expressed
as a percentage of the constriction induced by U46619. 
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Figure 2. Relaxations of PCAs,
preconstricted with U46619, to
bradykinin in the absence (control) or
presence of 100 µmol/l L-NAME, 300
µmol/l L-NAME or 100 µmol/l L-NOARG.
Data (mean±SEM of 6-9 experiments)
are expressed as a percentage of the
constriction induced by U46619. 
 
Chapter 5   
 76
When given separately, apamin, charybdotoxin, iberiotoxin, tetraethylammonium, BaCl2 
and ZnCl2 did not affect the bradykinin CRC (Figure 3, n=7 for each). Ouabain shifted 
the bradykinin CRC to the right (pEC50=6.9±0.3, n=7; P<0.01). This shift was not 
different from the shift observed in the presence of ouabain + BaCl2, suggesting that 
BaCl2 has no additional effect on top of ouabain.  
The S-nitrosothiol-depleting agent PHMBA reduced the maximum relaxant effect of 
bradykinin from 88±2% to 64±7% (n=6, P=0.01; Figure 4), without affecting its potency. 
Similar results were obtained with PHMBA in the presence of L-NAME (n=6). In 
contrast, the S-nitrosothiol-depleting agent ethacrynic acid (alone or on top of L-NAME) 
did not affect the bradykinin CRC (n=11, Figure 4). 
Thus, NO, S-nitrosothiols, IKCa and SKCa channels and Na+-K+-ATPase are involved in 
bradykinin-induced relaxations of PCAs. 
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Figure 3. Relaxations of PCAs, preconstricted with U46619, to bradykinin in the absence
(control) or presence of 100 nmol/l apamin (apa), 100 nmol/l charybdotoxin (char), 100 nmol/l
iberiotoxin (iber), 1 mmol/l tetraethylammonium (TEA), 30 µmol/l BaCl2 (Ba2+), 1 mmol/l ouabain
or 200 µmol/l ZnCl2 (Zn2+). Data (mean±SEM of 7 experiments) are expressed as a percentage
of the constriction induced by U46619.  
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NO-induced relaxation 
SNAP relaxed preconstricted vessel segments in a concentration-dependent manner 
(pEC50=6.4±0.1, n=21; Figure 5). Both hydroxocobalamin (pEC50=5.6±0.1, n=14; 
P<0.005) and ODQ (pEC50=5.3±0.1, n=13; P<0.001) shifted the SNAP-induced CRC to 
the right, and, in combination, completely blocked SNAP-induced relaxation (Figure 5). 
Charybdotoxin + apamin, as well as iberiotoxin + apamin, either together or on top of 
hydroxocobalamin or ODQ, did not induce a rightward shift of the SNAP CRC (Figures 5 
and 6; n=6-13). KCl (pEC50=6.0±0.2, n=10) and ouabain + BaCl2 (pEC50=5.7±0.2, n=8) 
comparably shifted the SNAP CRC to the right, although significance (P=0.02) was 
reached for ouabain + BaCl2 only. When given separately, BaCl2 (n=8) did not affect the 
SNAP CRC, whereas ouabain (pEC50=6.1±0.3, n=8; P=0.02) induced a similar rightward 
shift as ouabain + BaCl2 (Figures 5 and 7). 
Thus, relaxations induced by exogenous NO depend on guanylyl cyclase and Na+-K+-
ATPase. 
10 9 8 7 6
- log [bradykinin] mol/L
0
20
40
60
80
100
%
 re
la
xa
tio
n
10 9 8 7 6
- log [bradykinin] mol/L
0
20
40
60
80
100
%
 re
la
xa
tio
n
control
ethacrynic acid
L-NAME
L-NAME+ethacrynic acid
control
PHMBA
L-NAME
L-NAME+PHMBA
Figure 4. Relaxations of PCAs, preconstricted with U46619, to bradykinin in the absence
(control) or presence of 100 µmol/l L-NAME and/or 50 µmol/l ethacrynic acid and 10 µmol/l
PHMBA. Data (mean±SEM; n=6-11) are expressed as a percentage of the constriction induced
by U46619. 
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Figure 5. Relaxations of PCAs, preconstricted with U46619, to SNAP in the absence (control) or
presence of 10 µmol/l ODQ, 200 µmol/l hydroxocobalamin (HC), 100 nmol/l charybdotoxin
(char) + 100 nmol/l apamin (apa), 100 nmol/l iberiotoxin (iber) + 100 nmol/l apamin, 20 mmol/l
KCl or 1 mmol/l ouabain + 30 µmol/l BaCl2 (Ba2+). Data (mean±SEM; n=6-21) are expressed as
a percentage of the constriction induced by U46619. 
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Figure 6. Relaxations of PCAs, preconstricted with U46619, to SNAP in the absence (control) or
presence of one or more of the following inhibitors: 10 µmol/l ODQ, 200 µmol/l
hydroxocobalamin (HC), 100 nmol/l charybdotoxin (char), 100 nmol/l apamin (apa) and 100
nmol/l iberiotoxin (iber). Data (mean±SEM; n=6-13) are expressed as a percentage of the
constriction induced by U46619. 
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S-nitrosothiol-induced relaxation  
Both L-SNC (pEC50=6.3±0.3, n=20) and D-SNC (pEC50=5.9±0.2, n=15) relaxed 
preconstricted PCAs in a concentration-dependent manner (Figure 8). ODQ and 
hydroxocobalamin shifted the CRCs of both L-SNC (pEC50’s 4.2±0.1 and 4.3±0.1, n=6; 
P<0.01) and D-SNC (pEC50’s 4.6±0.3 and 4.2±0.1, n=5-6; P<0.01) >10 fold to the right 
and, when combined, nearly completely prevented the L-SNC- and D-SNC-induced 
effects. Charybdotoxin + apamin shifted the L-SNC CRC (pEC50=5.5±0.2, n=14; 
P=0.02), but not the D-SNC CRC, 5-10 fold to the right. Endothelium-denudation (n=7) 
did not prevent L-SNC-induced relaxations, nor did iberiotoxin + apamin (n=7) affect the 
L-SNC CRC (Figure 9). KCl (pEC50=5.0±0.1, n=7; P<0.01) and ouabain + BaCl2 
(pEC50=5.0±0.3, n=7; P=0.04) shifted the L-SNC CRC to the right. When given on top of 
ODQ and hydroxocobalamin, ouabain + BaCl2, but not charybdotoxin + apamin, 
iberiotoxin + apamin or KCl, fully blocked the L-SNC-induced effects (Figure 9, n=9 for 
all). When given separately, BaCl2 (n=6) did not affect the L-SNC CRC, whereas ouabain 
(pEC50=4.8±0.1, n=6; P=0.03) induced a similar rightward shift as ouabain + BaCl2 
(Figures 7 and 9). 
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Figure 7. Relaxations of PCAs, preconstricted with U46619, to SNAP, L-SNC or L-SNG in the
absence (control) or presence of 30 µmol/l BaCl2 (Ba2+) or 1 mmol/l ouabain. Data (mean±SEM;
n=6-8) are expressed as a percentage of the constriction induced by U46619. 
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Figure 8. Relaxations of PCAs, preconstricted with U46619, to L-SNC or D-SNC in the absence
(control) or presence of one or more of the following inhibitors: 10 µmol/l ODQ, 200 µmol/l
hydroxocobalamin (HC), 100 nmol/l charybdotoxin (char) and 100 nmol/l apamin (apa). Data
(mean±SEM; n=5-20) are expressed as a percentage of the constriction induced by U46619. 
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Figure 9. Relaxations of intact or endothelium-denuded PCAs, preconstricted with U46619, to L-
SNC without (left panel) or with 10 µmol/l ODQ and 200 µmol/l hydroxocobalamin (right panel) in
the absence (control and no endothelium) or presence of 100 nmol/l charybdotoxin (char) + 100
nmol/l apamin (apa), 100 nmol/l iberiotoxin (iber) + 100 nmol/l apamin, 20 mmol/l KCl or 1
mmol/l ouabain + 30 µmol/l BaCl2 (Ba2+). Data (mean±SEM; n=7-20) are expressed as a
percentage of the constriction induced by U46619. 
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Results obtained with L-SNG (pEC50=6.6±0.2, n=9; Figure 10) were identical to those 
with L-SNC, in that ODQ (pEC50=5.0±0.1, n=9; P<0.001 vs. control), hydroxocobalamin 
(pEC50=5.4±0.1, n=9; P<0.001), charybdotoxin + apamin (pEC50=6.0±0.2, n=9; P=0.04) 
and ouabain + BaCl2 (pEC50=4.8±0.3, n=9; P<0.01) all shifted the L-SNG CRC to the 
right. In addition, ouabain + BaCl2 reduced the maximal relaxant effect of L-SNG from 
95±3% to 46±11% (P<0.001). Results with ouabain alone (pEC50=5.6±0.3, n=6; P=0.04) 
were identical to those with ouabain + BaCl2 (Figures 7 and 10). BaCl2 alone (n=6) did 
not affect L-SNG (Figure 7). 
Thus, S-nitrosothiol-induced relaxation occurs in a stereoselective manner and depends 
on guanylyl cyclase, IKCa and SKCa channels and Na+-K+-ATPase. 
 
KCl-induced relaxation 
KCl relaxed preconstricted PCAs in a concentration-dependent manner. At a 
concentration of 2.5 mmol/l KCl, relaxation amounted to 30±4% of the U46619-induced 
preconstriction (n=7), and 7.5 mmol/l KCl relaxed preconstricted vessels by 45±7%. In 
contrast, 17.5 mmol/l KCl induced a constrictor response (corresponding with 18±1% of 
the maximum contraction) on top of the U46619-induced preconstriction.  
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Figure 10.  Relaxations of PCAs, preconstricted with U46619, to L-SNG without (control) or with
10 µmol/l ODQ, 200 µmol/l hydroxocobalamin, 100 nmol/l charybdotoxin (char) + 100 nmol/l
apamin (apa) or 1 mmol/l ouabain + 30 µmol/l BaCl2 (Ba2+). Data (mean±SEM; n=9) are
expressed as a percentage of the constriction induced by U46619. 
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Thus, low concentrations of KCl induce relaxation, and high (depolarizing) 
concentrations induce constriction.  
 
Discussion 
 
In the present study, bradykinin-induced, EDHF-mediated vasodilation in PCAs was 
found to involve IKCa and SKCa channels and Na+-K+-ATPase, in agreement with a recent 
proposal by Busse et al..61 It does not involve BKCa channels, two-pore domain K+ 
channels (TASK-1), KIR channels or (as shown in a previous study54) ATP-dependent K+ 
channels. The NO donor SNAP, in addition to its well-known effects on guanylyl 
cyclase, also activated Na+-K+-ATPase. SNAP did not affect Ca2+-dependent K+-
channels, thereby confirming that, in PCAs, NO is not EDHF. Finally, the nitrosothiols 
L-SNC and L-SNG, but not D-SNC, on top of their relaxant effects via the NO-guanylyl 
cyclase-cGMP pathway, activated IKCa and SKCa channels, and Na+-K+-ATPase. This 
finding, combined with our observation that the nitrosothiol-depleting agent PHMBA 
reduced the maximum relaxant effect of bradykinin, supports the concept that S-
nitrosothiols, in a stereoselective manner, mediate bradykinin-induced, EDHF-dependent 
effects in PCAs.  
Despite reports on EET- (a putative EDHF candidate) and NO-induced activation of 
BKCa channels,63,71,72 the selective BKCa channel inhibitor iberiotoxin did not affect the 
relaxant response to any of the agonists applied in the present study. 
Tetraethylammonium, at a concentration that selectively blocks BKCa channels,137 also did 
not affect the relaxant response to bradykinin. Thus, in PCAs, BKCa channels do not 
contribute to bradykinin-induced relaxation. In addition, based on the lack of effect of 
inhibitors of the cytochrome-P450 metabolism of arachidonic acid towards bradykinin in 
porcine and human coronary arteries,54,57,58 an EET is unlikely to be EDHF in these 
coronary arteries.   
Because of the lack of effect of BKCa channel blockade, the inhibitory effects of the non-
selective IKCa and BKCa channel inhibitor charybdotoxin in this study must have been due 
to blockade of IKCa channels. Charybdotoxin-induced blockade became apparent only in 
the presence of the SKCa channel inhibitor apamin, in agreement with the idea that both 
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IKCa and SKCa channels contribute to the EDHF response, and that blockade of one 
channel offers an ‘escape’ via the other.57,58,69,70,131 IKCa and SKCa channels reside in 
porcine coronary artery endothelial cells,70 and SKCa channels have also been 
demonstrated in smooth muscle cells.124 Thus, the IKCa and SKCa channel-dependent 
effects of L-SNC and L-SNG may have resulted in hyperpolarization of both endothelial 
and smooth muscle cells. In support of the latter, L-SNC also relaxed de-endothelialized 
PCAs. However, this cannot be taken as unequivocal evidence for the activation of Ca2+-
dependent K+-channels on smooth muscle cells by S-nitrosothiols, since it may well be 
explained by the activation of guanylyl cyclase through the decomposition of L-SNC and 
L-SNG to NO.  
Endothelial IKCa and SKCa channel activation results in modest K+ accumulation in the 
myo-endothelial space. This K+ is believed to subsequently hyperpolarize vascular 
smooth muscle cells by activating Na+-K+-ATPase and/or KIR channels.61,64,65,132 We tested 
this hypothesis by studying the relaxant effects of KCl in PCAs. Indeed, in agreement 
with a study in porcine renal arteries,132 low (<10 mmol/l) KCl concentrations relaxed 
preconstricted vessels, whereas higher (depolarizing) concentrations induced constriction. 
KIR channels did not contribute to the relaxations observed in our experimental setup, as 
BaCl2 (alone or on top of ouabain) did not exert a blocking effect towards bradykinin, 
SNAP, L-SNC or L-SNG. Since NO itself was also found to activate Na+-K+-ATPase, 
both endothelial IKCa and SKCa channel activation and decomposition to NO may 
underlie the S-nitrosothiol-induced activation Na+-K+-ATPase. 
Direct activation of Ca2+-dependent K+-channels by S-nitrosothiols has been 
demonstrated before.77,124 Such activation most likely involves ‘nitrosation motifs’ within 
the ion channels.115 For instance, in the BKCa channel, the cysteine residues within the α 
subunit have been identified as S-nitrosothiol binding sites.77 The stereoselectivity of this 
effect (Figure 8) confirms previous in vivo studies with S-nitrosothiols in rats.76  
The contribution of IKCa and SKCa channels to the relaxant effects of L-S-nitrosothiols 
appears to be more modest than the NO-related contribution. Complete blockade of the 
L-SNC-induced effects was obtained only in the presence of ODQ, hydroxocobalamin 
and ouabain. This supports the idea that, in the absence of NO, IKCa and SKCa channel 
activation results in K+ release and subsequent activation of Na+-K+-ATPase. However, 
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in contrast with this concept, IKCa and SKCa channel inhibition did not yield additional 
effects on top of blockade of the NO-guanylyl cyclase-cGMP pathway. This discrepancy 
may relate to incomplete or reversible inhibitory actions of both ODQ and 
hydroxocobalamin,54,58,127 which could become apparent at high agonist concentrations 
and/or during particular inhibitor combinations only.  
Although bradykinin-induced S-nitrosothiol release has not been demonstrated so far, our 
data with the S-nitrosothiol-depleting compound PHMBA (which reduced the relaxant 
effect of bradykinin by ≈30%, both in the presence and absence of NO) fully support this 
concept. Furthermore, endothelial and smooth muscle cells have been reported to contain 
preformed pools of NO-containing factors such as S-nitrosothiols.54,59,107,128 These pools 
become depleted after repeated exposure to endothelium-dependent agonists (e.g., 
bradykinin), following prolonged NOS inhibition, and after exposure to light.54,59,60,107 The 
thiol alkylating agent ethacrynic acid did not affect the bradykinin-induced relaxations in 
PCAs, possibly because this agent inhibits regeneration of the stores rather than directly 
inducing depletion.138 Both NOS and non-NOS sources are believed to contribute to the 
maintenance of NO stores.107,135,138  
In conclusion, our data support the concept that L-S-nitrosothiols mediate bradykinin-
induced, EDHF-dependent relaxation in PCAs. Moreover, they raise the possibility that 
L-S-nitrosothiols are EDHFs themselves. Thus, in addition to providing a new 
pharmacological route for delivering NO regionally,129 S-nitrosothiols could 
simultaneously exert EDHF-like actions. 
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Summary 
 
Recent trials have suggested favourable effects on diabetes onset and control of the non-
selective β+α1-adrenoceptor blocker carvedilol as compared to the selective β1-
adrenoceptor blocker metoprolol. Similar metabolic effects have been established for 
renin-angiotensin-system (RAS) blockers. Angiotensin (Ang) II type-1 (AT1)-α1-receptor 
crosstalk may provide a mechanism by which carvedilol affects the RAS. Accordingly, 
we examined the effects of selective versus non-selective β-adrenoceptor blockade on 
AT1 receptor-mediated vasoconstrictor responses to Ang II in human coronary 
microarteries (HCMAs), simulating both the hyperadrenergic and activated RAS states 
present in cardiovascular disease. Therefore, HCMAs, obtained from 23 heart valve 
donors, were mounted in myographs. Ang II and the α1-adrenoceptor agonist 
phenylephrine constricted HCMAs to maximally 57±15 and 56±25% of the contraction to 
100 mmol/L K+. Neither carvedilol, metoprolol, the nonselective β-adrenoceptor 
antagonist propranolol, nor the α1-adrenoceptor antagonist prazosin affected the 
constrictor response to Ang II. Thus, α1- and β-adrenoceptors are not involved in the 
direct constrictor effects of Ang II, nor do the anti-oxidant and anti-endothelin-1 
properties of carvedilol antagonize Ang II. Ang II, when added to the organ bath at a 
subthreshold concentration, greatly amplified the response to phenylephrine. Both 
carvedilol and the AT1 receptor antagonist irbesartan inhibited this Ang II-induced 
potentiation. Furthermore, carvedilol blocked the Ang II-induced amplification of 
phenylephrine-induced inositolphosphate accumulation in cardiomyocytes. In conclusion, 
AT1-α1-receptor crosstalk, involving inositolphosphates, sensitizes HCMAs to α1-
adrenoceptor agonists. Our results suggest that, in the presence of an increased 
sympathetic tone, carvedilol provides AT1 receptor blockade via its α1-adrenoceptor 
blocking effects. Herein lies an explanation for the favourable metabolic effects of 
carvedilol versus metoprolol.  
  Carvedilol-induced antagonism of Ang II 
 87
Introduction 
 
Diabetes mellitus is a co-morbidity with adverse prognostic impact in subjects with 
cardiovascular disease and its incidence and progression is favorably affected by 
blockade of the renin-angiotensin system (RAS) in a dose-dependent fashion.139-141 Recent 
evidence obtained in subjects with chronic heart failure (CHF)142 as well as 
hypertension143 further suggests that the incidence and progression of diabetes mellitus 
may be differentially affected by selective (metoprolol) versus non-selective (carvedilol) 
β-adrenoceptor blockade in subjects already treated with RAS-blocking agents. The 
precise mechanism for this effect of carvedilol remains to be elucidated. Interestingly, it 
has recently been demonstrated that subjects with CHF treated chronically with carvedilol 
are less sensitive to angiotensin (Ang) II than subjects treated with metoprolol.144 It is 
conceivable that this potentiation of RAS blockade impacts metabolic control in a similar 
manner as an increase in the dose of a RAS blocker.141   
Several mechanisms could underlie the carvedilol-induced antagonism of Ang II: First, 
α1-Ang II type 1 (AT1)-receptor crosstalk (e.g., due to heterodimerization) greatly 
sensitizes α1-adrenoceptor-mediated responses in the presence of subthreshold 
concentrations of Ang II.145,146 Carvedilol, being an α1-adrenoceptor antagonist, will block 
such Ang II-dependent potentiation. Second, carvedilol inhibits the synthesis of both 
endothelin-1 (ET-1) and superoxide,147,148 two mediators of Ang II-induced responses.82,149 
Third, carvedilol stimulates NO release from endothelial cells through ATP efflux150 and 
might thus counteract Ang II-induced hypertensive responses.40 Finally, Barki-Harrington 
et al.151 recently reported a direct interaction between β-adrenoceptors and AT1 receptors 
in mouse cardiomyocytes, allowing dual inhibition of both receptors by either the non-
selective β-adrenoceptor antagonist propranolol or the AT1 receptor antagonist valsartan.  
In the present study we investigated the effect of selective versus non-selective β-
adrenoceptor blockade on Ang II-induced vasoconstriction in human coronary 
microarteries (HCMAs). We also addressed the precise mechanism of this effect, using 
both HCMAs and isolated cells.   
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Methods 
 
Human tissue collection 
HCMAs were obtained from 23 heart-beating organ donors (9 men, 14 women, age 13-61 
years, mean 45 years), who died of non-cardiac causes (1 cerebrovascular accident, 8 
head trauma, 7 subarachnoid bleeding, 1 post-anoxic encephalopathy, 6 intracranial 
bleeding) <24 hours before the heart was taken to the laboratory. Hearts were provided by 
the Rotterdam Heart Valve Bank after removal of the heart valves for transplantation 
purposes. The study was approved by the Ethics Committee of the Erasmus MC. The 
hearts were stored in an ice-cold sterile organ-protecting solution after circulatory arrest. 
After arrival at the laboratory, a tertiary branch of the left anterior descending coronary 
artery (diameter, 240-500 µm; mean 320 µm) was removed and stored overnight in a cold 
(4°C), oxygenated Krebs bicarbonate solution of the following composition (mmol/L): 
NaCl 118, KCl 4.7, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25 and glucose 8.3; pH 
7.4.  
 
Myograph studies 
Following overnight storage, HCMAs were cut into segments of ≈2 mm length and 
mounted in a Mulvany myograph (J.P. Trading) with separated 6-mL organ baths 
containing oxygenated Krebs at 37°C. The Krebs was continuously aerated with 95% O2 
and 5% CO2, and tissue responses were measured as changes in isometric force, using a 
Harvard isometric transducer. After a 30-minute stabilization period, the optimal internal 
diameter was set to a tension equivalent to 0.9 times the estimated diameter at 100 mm 
Hg effective transmural pressure as described before.47 Endothelial integrity was verified 
by observing relaxation to 10 nmol/L substance P after preconstriction with 10 nmol/L of 
the thromboxane A2 analogue U46619 (Sigma). Subsequently, to determine the 
maximum contractile response, the tissue was exposed to 100 mmol/L KCl. The 
segments were then allowed to equilibrate in fresh organ bath fluid for 30 min. Next, 
segments were pre-incubated for 30 minutes with carvedilol (a gift of Roche), metoprolol 
(Sigma), propranolol (Sigma), prazosin (Sigma), irbesartan (a gift of Bristol-Myers 
Squibb) or eprosartan (a gift of SmithKline-Beecham). Thereafter, concentration-
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response curves (CRCs) were constructed to Ang II, endothelin-1 (ET-1) and/or 
phenylephrine. The cyclo-oxygenase inhibitor indomethacin (5 µmol/L) was present 
during the entire experiment to suppress spontaneously occurring contractions and 
relaxations. 
 
Inositolphosphate generation in cardiomyocytes 
Primary cultures of neonatal rat ventricular cardiomyocytes were prepared as described 
before.13 Cells were labelled with 2 µCi myo-[2-3H]inositol/mL for 24 hours, washed, and 
preincubated for 10 minutes with vehicle, carvedilol or irbesartan. Next, the cells were 
stimulated for 30 minutes with phenylephrine and/or Ang II in the presence of 10 mmol/L 
LiCl to inhibit inositolmonophosphatase activity. Intracellular water-soluble 
inositolphosphates (InsPn) were then separated and quantified as described before.13  
 
Bioluminescence Resonance Energy Transfer (BRET) 
Enhanced yellow fluorescent protein (eYFP) was appended to the C-terminal tail of the 
human AT1 receptor from which the stop codon was eliminated, and the human α1B-
adrenoceptor was modified by C-terminal, in-frame addition of Renilla luciferase. The 
α1B-adrenoceptor was chosen because it represents the major α1-adrenoceptor subtype in 
human arteries.152 In addition, carvedilol inhibits α1B-adrenoceptor-mediated effects with 
high potency (pKi=8.6).153 HEK293 cells were transfected with the two receptors and 
harvested after 48 hours as described before.154 Cells were then suspended in phosphate-
buffered saline and mixed (1:1) with 10 µmol/L h-coelenterazine. eYFP will act as a 
resonance energy transfer acceptor for light emitted by the oxidation of h-coelenterazine 
by Renilla luciferase only if the two receptors are within 50-100 Å.155 Immediately after 
the addition of h-coelenterazine, using a Spex fluorolog spectrofluorimeter, the emission 
spectrum (400-600 nm) was acquired with the excitation lamp turned off (slit width=10 
nm, 2 sec/increment). For comparisons between experiments, emission spectra were 
normalized with the peak emission from Renilla luciferase in the region of 480 nm being 
defined as an intensity of 1.00. Energy transfer signal was calculated by measuring the 
area under the curve between 500 nm and 550 nm. Background was taken as the area of 
this region of the spectrum when examining emission of cells expressing only the energy 
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donor. Energy acceptor to energy donor expression ratios were measured as described 
previously.154 
 
Data analysis 
Data are given as mean±SEM. Contractile responses are expressed as a percentage of the 
contraction to 100 mmol/L K+. CRCs were analyzed as described to obtain pEC50 (-
10log50) values.46 In order to compare the effects of the various agents, the amounts of 
InsPn were expressed as a percentage of the total cellular amount of [2-3H]inositol-
labeled products. Statistical analysis was by paired t-test or ANOVA, followed by post 
hoc evaluation according to Dunnet. P<0.05 was considered significant.  
 
Results 
 
Myograph Studies  
Ang II (n=9), ET-1 (n=5) and phenylephrine (n=9) constricted HCMAs in a 
concentration-dependent manner (pEC50’s: 8.5±0.1, 8.2±0.1 and 4.8±0.2; Emax 57±15, 
121±16 and 56±25% of the contraction to 100 mmol/L K+; Figure 1). Carvedilol (n=6), 
metoprolol (n=6), propranolol (n=7), and prazosin (n=8), all at a concentration of 10 
µmol/L, did not affect the Ang II CRC (Figure 2). Prior application of 1 nmol/L Ang II to 
the organ bath greatly amplified the maximum response to phenylephrine (Emax 113±28 
vs. 56±25%, n=6; P<0.01), without altering the pEC50. No such amplification was 
observed following prior application of 1 nmol/L ET-1 (Emax 64±17 vs 58±36%, n=4;  
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Figure 1. Top panels, contractions of HCMAs to Ang II or endothelin-1. Bottom panels,
contractions of HCMAs to phenylephrine in the absence (control) or presence of 1 nmol/L Ang
II, 1 nmol/L Ang II + 10 µmol/L carvedilol, or 1 nmol/L endothelin-1.  Contractions
(mean±SEM, n=3-9) are expressed as a percentage of the response to 100 mmol/L K+. *,
P<0.01. 
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Figure 2.  Contractions of HCMAs to Ang II in the absence (control) or presence of carvedilol,
metoprolol, propranolol, or prazosin, all at a concentration of 10 µmol/L. Contractions
(mean±SEM, n=5-8) are expressed as a percentage of the response to 100 mmol/L K+.  
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P=NS), although the vasoconstriction induced by this concentration of ET-1 (4.0±3.4%) 
was not significantly different from that induced by 1 nmol/L Ang II (13.6±3.3%). 
Carvedilol (10 µmol/L; n=3) fully prevented the phenylephrine-induced effects in the 
presence of Ang II (Figure 1).  
Irbesartan (n=5) concentration-dependently inhibited the Ang II-induced increase in 
phenylephrine efficacy, fully reversing the potentiation at a concentration of 100 nmol/L 
and higher (Figure 3). The inhibitory profile of irbesartan towards phenylephrine in the 
presence of 1 nmol/L Ang II was indistinguishable from that towards Ang II (Figure 3). 
Furthermore, neither 1 µmol/L irbesartan (n=5) nor 1 µmol/L eprosartan (n=5) affected  
the phenylephrine-induced responses in the absence of Ang II (data not shown). 
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Figure 3. Contractions of HCMAs to phenylephrine in the presence of 1 nmol/L Ang II (left)
and to Ang II (right) at increasing concentrations of irbesartan. Contractions (mean±SEM; n=4-
5) are expressed as a percentage of the response to 100 mmol/L K+. The phenylephrine
CRCs in the presence of the two highest irbesartan concentrations are indistinguishable from
the phenylephrine CRC in the absence of this inhibitor (see Figure 2). Note that the inhibitory
profile of irbesartan towards the Ang II-dependent component is identical in the two graphs. 
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Inositolphosphate generation in cardiomyocytes 
Phenylephrine stimulated InsPn accumulation in neonatal rat cardiomyocytes in a 
concentration-dependent manner (Figure 4, n=3). Carvedilol (10 µmol/L) fully blocked 
this effect (n=3). In agreement with a previous study,13 10 nmol/L Ang II (n=3) did not 
significantly affect InsPn accumulation. However, this concentration of Ang II amplified 
the response to 1 µmol/L phenylephrine, an effect that was abolished by 10 µmol/L 
carvedilol (n=3 for all conditions). 
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Figure 4. Left panel, concentration-dependent effect of phenylephrine (PE) on
inositolphosphate (InsPn) accumulation in neonatal rat cardiomyocytes. Right panel, effect of 1
µmol/L phenylephrine and/or 10 nmol/L angiotensin II (Ang II) in the absence or presence of
10 µmol/L carvedilol (carv) on InsPn accumulation in neonatal rat cardiomyocytes. Data are
mean±SEM of 3 experiments each. Phenylephrine increased InsPn accumulation in all 3
experiments at concentrations ≥ 1 µmol/L (*). Ang II increased the effect of phenylephrine in
all 3 experiments (†), and carvedilol reduced the effect of phenylephrine both without (‡) and
with Ang II (§) in all 3 experiments. 
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BRET 
Co-expression of the α1B-adrenoceptor C-terminally tagged with Renilla luciferase and 
the AT1 receptor with eYFP in HEK293 cells, followed by the addition of h-
coelenterazine, generated a major peak in the region of 480 nm (representing light output 
from the oxidation of the substrate by the luciferase) and a second peak (representing 
resonance energy transfer between luciferase and eYFP), centred at 527 nm (Figure 5). 
This is consistent with the hypothesis that the two receptors are able to form a 
constitutive oligomeric complex. The signal generated was of similar magnitude to that 
reported previously for the interaction between the AT1 receptor and a second G-protein-
coupled receptor, the Mas proto-oncogene.156 
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Figure 5. Panel A, Hetero-oligomeric interaction following co-expression of the α1B-
adrenoceptor-Renilla luciferase and the AT1 receptor-eYFP in HEK293 cells. A fusion protein
incorporating the sequences of both Renilla luciferase and eYFP serves as a BRET-positive
control.(Ramsay et al., 2002) c.p.s., counts per second. Panel B, Quantitation of the area
under the peak from 500-550 nm. Data are mean±SEM of 3 experiments. 
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Discussion 
 
Ang II stimulates the sympathetic nervous system in a number of ways, including a 
central action to improve sympathetic outflow,157,158 together with a facilitation of the 
release of catecholamines from peripheral sympathetic neurons via ganglionic and axonal 
presynaptic receptors.159,160 In addition, Ang II increases the vascular sensitivity to α1-
adrenoceptor agonists.146 Indirect confirmation of this concept in humans has come from a 
study in which the ACE inhibitor perindoprilat attenuated the forearm blood flow 
response to exogenous norepinephrine.161 The present study is the first to directly confirm 
Ang II-induced potentiation of α1-adrenoceptor agonists in HCMAs. Potentiation was not 
observed after application of a subthreshold concentration of ET-1 to the organ bath, and 
thus, this effect is specific for Ang II. Furthermore, the lack of effect of prazosin towards 
Ang II excludes the possibility that release of endogenous norepinephrine (through 
stimulation of presynaptic AT1 receptors) contributed to the vasoconstrictor effect of Ang 
II in this preparation. 
Irbesartan blocked the Ang II-induced potentiation of phenylephrine in a concentration-
dependent manner. The inhibitory profile of the AT1 receptor antagonist towards the 
potentiating effects of Ang II was indistinguishable from that towards the direct 
constrictor effects of Ang II. At irbesartan concentrations of 100 nmol/L and higher, the 
effects of phenylephrine were identical to those without Ang II, and neither irbesartan nor 
eprosartan interfered with phenylephrine in the absence of Ang II. Thus, the potentiating 
effects of Ang II depend on AT1 receptor activation, and do not involve direct α1-
adrenoceptor stimulatory effects. Consequently, AT1 receptors and α1-adrenoceptors may 
interact physically (e.g., through heterodimerization), and/or the Ang II-induced 
amplification results from changes in a common signaling process regulating contractility 
or from crosstalk between different signaling processes. Our data support both 
possibilities. BRET confirms the potential for constitutive physical association between 
the two receptor types, and the inositolphosphate data are in full agreement with the fact 
that both receptors couple to Gq/11, and, through activation of phospholipase Cβ, promote 
the hydrolysis of phosphatidylinositol 4,5- bisphosphate into inositol 1,4,5-trisphosphate 
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and sn-1-2 diacylglycerol.162,163 The latter molecule activates isoforms of protein kinase C, 
which have already been shown to contribute to the Ang II-induced amplification of α1-
adrenoceptor agonists in rabbits.164   
Carvedilol inhibited both the enhanced vasoconstriction to phenylephrine and the 
increased inositolphosphate accumulation in the presence of Ang II. It did not block the 
direct constrictor effects of Ang II in HCMAs. This implies that ET-1 and superoxide 
(which are both blocked by carvedilol147,148) do not mediate the effects of Ang II, in 
agreement with a previous study in human coronary arteries,52 and that the carvedilol-
induced release of NO from endothelial cells,150 if occurring in HCMAs, is insufficient to 
counteract the Ang II-induced vasoconstriction. Taken together therefore, particularly in 
view of the increased sympathetic tone in chronic heart failure, the α1-adrenoceptor 
blocking effects of carvedilol most likely underlie its capacity to antagonize angiotensin 
II. Such antagonism may be expected to exert additional effects on top of RAS blockade 
in chronic heart failure, since the ACE inhibitors and/or AT1 receptor antagonists that are 
currently being used do not fully suppress the RAS. Either they are dosed too low165 or 
their effects are overcome, at least in part, by the reactive rise in renin release,166 ACE 
upregulation167 and/or alternative converting enzymes like chymase.53 Thus, carvedilol 
blocks the RAS in two ways: it inhibits renin release through blockade of renal β1-
adrenoceptors, and it prevents the functional consequences of α1-AT1-receptor 
interaction. As the latter does not apply to the selective β1-adrenoceptor antagonist 
metoprolol, this additional property could underlie the favourable metabolic profiles in 
subjects with heart failure or hypertension treated with carvedilol as compared to 
metoprolol.142,143 
Our data do not support a direct interaction between β-adrenoceptors and AT1 receptors 
in HCMAs. Such interaction has been reported in mouse cardiomyocytes,151 allowing 
propranolol and the AT1 receptor antagonist valsartan to block both Ang II- and 
isoproterenol-induced contractile responses. At least two explanations for this 
discrepancy may be put forward. First, the interaction may be limited to β1-
adrenoceptors, whereas HCMAs contain β2-adrenoceptors.168 Second, unlike the 
comparable (positive inotropic) effects of β-adrenoceptors and AT1 receptors in 
cardiomyocytes, β2-adrenoceptors and AT1 receptors exert opposite effects in 
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HCMAs,47,168 and thus, if anything, propranolol would be expected to enhance Ang II-
induced vasoconstriction. For instance, blockade of vasodilator AT2 receptors (which also 
heterodimerize with AT1 receptors35) increases the Ang II-induced constriction in 
HCMAs.47 The fact that β2-adrenoceptor blockade did not enhance Ang II-induced 
vasoconstriction confirms the absence of endogenous catecholamines in this preparation.       
In summary, we report for the first time that α1-AT1-receptor crosstalk is of functional 
importance in human coronary arteries. Our findings provide a mechanism that could 
explain the results of clinical studies comparing metoprolol and carvedilol in 
cardiovascular diseases states.  
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Summary 
 
Introduction and aim (Chapter 1) 
Angiotensin (Ang) II induces vasorelaxation via activation of Ang II type 2 (AT2) 
receptors. This effect most likely depends on endothelial bradykinin type 2 (B2) receptor-
induced NO release, suggesting that AT2 receptors either stimulate bradykinin release 
and/or couple directly (e.g., through heterodimerization) to B2 receptors in a bradykinin-
independent manner. B2 receptor stimulation also results in the release of a wide range of 
non-NO endothelium-derived hyperpolarizing factors (EDHFs) like K+, prostacyclin, 
epoxyeicosatrienoic acids (EETs), H2O2 and S-nitrososothiols. Consequently, some or all 
of these EDHFs might simultaneously contribute to the AT2 receptor-mediated 
vasorelaxation. It was the aim of the present thesis to study AT2 receptor-induced 
vasodilation in humans, and to focus further on the identity of EDHF. In addition, the 
interaction between AT1 and α1-adrenergic receptors was studied in order to obtain an 
explanation for the Ang II-antagonistic effects of the non-selective β- and α1-
adrenoceptor antagonist carvedilol. 
 
AT2 receptors and vasorelaxation in humans (Chapter 2) 
Ang II constricted human coronary microarteries (HCMAs) through activation of AT1 
receptors. Pre-incubation of HCMA segments with the AT2 receptor antagonist 
PD123319 increased the constrictor effect of Ang II, a phenomenon that was particularly 
present in older subjects and that was abolished after endothelium removal and during 
blockade of either B2 receptors or NO synthase (NOS). Exposure of preconstricted 
HCMAs to Ang II in the presence of the AT1 receptor antagonist irbesartan (allowing 
selective AT2 receptor activation) resulted in relaxation. PD123319 fully abolished this 
effect. Radioligand binding studies and RT-PCR confirmed the expression of AT1 and 
AT2 receptors in HCMAs. Taken together, these data are the first to support AT2 
receptor-mediated vasodilation in human coronary arteries. This effect depends on  
endothelial B2 receptors and NO, and appears to increase with age.  
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The identity of EDHF (Chapters 3, 4 and 5) 
To obtain further insight into the identity of EDHF, bradykinin-induced vasorelaxation 
was studied in HCMAs, porcine coronary microarteries (PCMAs) and large porcine 
coronary arteries (PCAs), both in the absence and presence of inhibitors of NO and/or 
EDHF. 
As expected, the contribution of de novo synthesized NO was more important in large 
arteries than in microarteries. In all vessels, the NO scavenger hydroxocobalamin induced 
a greater degree of inhibition towards bradykinin than the NOS inhibitor L-NAME. This 
suggests that NO can also be released from a source other than L-arginine, e.g., from NO-
containing factors like S-nitrosothiols. 
In the absence of NO, full inhibition of the bradykinin response was obtained during 
combined blockade of intermediate- and small-conductance Ca2+-dependent K+-channels 
(IKCa, SKCa), and in the presence of the Na+/K+-ATPase inhibitor ouabain. Ouabain also 
diminished the response to the NO donor SNAP, whereas combined IKCa and SKCa 
channel blockade did not. Furthermore, inhibitors of catalase, cyclooxygenase (COX), 
cytochrome P450 epoxygenase, gap junctions and large-conductance Ca2+-activated K+-
channels (BKCa) did not interfere with bradykinin-mediated responses. 
Taken together, these findings suggest that bradykinin-induced relaxation in human 
and porcine coronary arteries depends on activation of guanylyl cyclase and Na+/K+-
ATPase by NO, and activation of IKCa and SKCa channels by a factor other than NO. This 
factor is not prostacyclin, a cytochrome P450 product, or H2O2, nor does it depend on gap 
junctions and BKCa channels. The following evidence was obtained to support that this 
factor may be a S-nitrosothiol: 1) L-S-nitrosocysteine (L-SNC) relaxed PCMAs and 
PCAs, and this effect was diminished during combined IKCa and SKCa channel blockade 
in the presence but not in the absence of the endothelium, 2) L-SNC hyperpolarized 
vascular smooth muscle cells in PCAs, and 3) S-nitrosothiol-depleting agents reduced the 
response to bradykinin. Interestingly, combined IKCa and SKCa channel blockade did not 
affect the response to D-S-nitrosocysteine. Thus, S-nitrosothiols, via stereoselective 
activation of endothelial IKCa and SKCa channels, may function as EDHF. In addition, 
due to their decomposition to NO, these factors may provide an alternative source of NO. 
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AT1 and α1-adrenergic receptor interaction (Chapter 6) 
Neither carvedilol, the selective β1-adrenoceptor antagonist metoprolol, the nonselective 
β-adrenoceptor antagonist propranolol, nor the α1-adrenoceptor antagonist prazosin 
affected the constrictor response to Ang II in HCMAs. Ang II, when added to the organ 
bath at a subthreshold concentration, greatly amplified the response to the α1-
adrenoceptor agonist phenylephrine. Both carvedilol and the AT1 receptor antagonist 
irbesartan inhibited this Ang II-induced potentiation. Furthermore, carvedilol blocked the 
Ang II-induced amplification of phenylephrine-induced inositolphosphate accumulation 
in neonatal rat cardiomyocytes. Thus, AT1-α1-receptor crosstalk, involving 
inositolphosphates, sensitizes HCMAs to α1-adrenoceptor agonists. Its α1-adrenoceptor 
blocking effects allow carvedilol to antagonize Ang II in the face of increased 
sympathetic activity, e.g., in subjects with chronic heart failure. 
 
General Discussion and Future Studies  
 
AT2 receptors and vasodilation in humans 
Animal studies from many groups around the world support the idea that AT2 receptors 
mediate vasodilation.5,18,22,24,33,87,88,101 Our in vitro data are the first to confirm that such 
vasodilation also occurs in humans. The clinical relevance of AT2 receptor stimulation 
has not yet been fully established. AT2 receptors are upregulated under pathological 
conditions in the human heart,31,43 and their stimulation may underlie, at least in part, the 
beneficial effect of AT1 receptor antagonists in cardiovascular disease.44,45 The link 
between AT2 receptors and B2 receptors suggests that the (side-)effects of AT1 receptor 
antagonists, like those of ACE inhibitors, may depend on B2 receptor activation. Yet 
many questions remain: does AT2 receptor activation result in bradykinin release or do 
these receptor directly couple to B2 receptors without intermediate bradykinin synthesis? 
Our previous studies do not support the idea of bradykinin generation in isolated human 
vessels.47 Furthermore, since the net effect of Ang II depends on the AT1/AT2 receptor 
ratio, it needs to be established how and where these receptors interact. AT2 receptors 
occur predominantly on endothelial cells, whereas AT1 receptors are believed to be 
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located mainly on vascular smooth muscle cells. However, the opposite has also been 
reported,126 and thus the idea of heterodimerization35 may be relevant. Future studies in 
transgenic animals, allowing selective expression of these receptors, could shed light on 
this issue. Finally, we detected AT2 receptor expression in large human coronary arteries, 
but could not relate this to an effect on Ang II-induced contractility. Thus, the role of 
these receptors in large arteries still needs to be determined.    
 
The identity of EDHF 
Bradykinin relaxed human and porcine coronary arteries in the absence of de novo 
synthesized NO, through pathways that did not involve guanylyl cyclase-dependent 
cGMP generation. Thus, an EDHF that is not de novo synthesized NO contributes to the 
relaxant effects of bradykinin in a cGMP-independent manner.  
A recent study in endothelial NOS (eNOS)/COX-1 double-knockout mice169 suggests 
that EDHF is the predominant endothelium-derived relaxing factor in female mice. Our 
human data support this conclusion, because the effect of NO blockade on bradykinin-
induced relaxation of HCMAs was larger in men than in women. Possibly therefore, 
estrogens upregulate the EDHF pathway.79,80,170 Further work is needed to unravel this 
issue. 
Combined blockade of IKCa and SKCa channels (with charybdotoxin and apamin, 
respectively) fully inhibited the EDHF-mediated responses in our experimental setup, as 
well as in the above double-knockout mice.169 These channels are located in endothelial 
cells.61 Their activation results in the release of K+ into the myo-endothelial space. This 
K+ is capable of hyperpolarizing vascular smooth muscle cells by activating inwardly 
rectifying K+ (KIR) channels and/or Na+/K+-ATPase.61,64,65,132 Consequently, combined 
blockade of KIR channels and Na+/K+-ATPase (with Ba2+ and ouabain, respectively) 
should also inhibit EDHF-mediated responses. Our data support this contention, although, 
at least in PCAs, Ba2+ did not exert effects on top of ouabain. Moreover, we and others108 
observed that NO donors also activate Na+/K+-ATPase. Thus, future studies should 
delineate to what degree bradykinin-induced Na+/K+-ATPase activation depends on NO 
and/or EDHF. 
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Unlike several other groups,63,71,72 we were unable to obtain evidence supporting a role 
for EETs (generated from arachidonic acid by cytochrome P450 epoxygenases) as EDHF. 
A recent study in human coronary arterioles171 offers an explanation for this discrepancy. 
It was found that H2O2 inhibited the bradykinin-induced generation of EETs as well as 
the BKCa channels that normally mediate the EET-induced hyperpolarization of vascular 
smooth muscle cells. Thus, the contribution of EETs in HCMAs needs to be re-addressed 
on top of hydroxocobalamin and catalase. A complicating factor in this regard is that 
cytochrome P450 epoxygenases also generate superoxide, the precursor of H2O2.172 
We propose that S-nitrosothiols act as EDHF in coronary (micro-)arteries. NO reacts 
with thiols in proteins such as albumin and hemoglobin to form S-nitrosoalbumin and S-
nitrosohemoglobin. These S-nitrosothiols are believed to provide a reservoir of NO 
bioactivity, although controversy exists with regard to their concentrations in blood. As a 
consequence of differences in sample handling and detection methods, plasma levels of 
S-nitrosothiols range from 10 nmol/L to 10 µmol/L.173 Perhaps more important than level 
is the S-nitrosothiol throughput.174 Depletion of ascorbate reduces the release of NO from 
S-nitrosothiols, and this may explain why the higher circulating levels of S-
nitrosoalbumin in women with preeclampsia (who have 50% lower ascorbate levels than 
normal pregnant controls) do not result in more NO release.174 However, S-nitrosothiols 
induce relaxation not only through their decomposition to NO,75 but also by activating 
stereoselective recognition sites.120 Recently, the cysteine residues within the α subunit of 
the BKCa channel were identified as a S-nitrosothiol binding site.77 Our data extend these 
observations by providing evidence for stereoselective activation of endothelial IKCa and 
SKCa channels by L-S-nitrosocysteine and L-S-nitrosoglutathion and (subsequent) 
vascular smooth muscle cell hyperpolarization.  
Electrophysiological studies should now further substantiate these findings, 
investigating in particular which Ca2+-activated K+ channel(s) in which cell(s) can be 
activated by S-nitrosothiols. Simultaneously, it should be studied to what degree NO 
release determines S-nitrosothiol-induced coronary vasorelaxation, and how this can be 
influenced by vitamin C. Furthermore, in view of the findings in eNOS knockout mice,169 
the S-nitrosothiol levels in such animals should be measured, considering the fact that 
inducible NOS and/or neuronal NOS may also contribute to the generation of S-
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nitrosothiols.107,175 It is also of importance to demonstrate bradykinin-induced release of S-
nitrosothiols. This may prove to be difficult, because such release could be limited to a 
specific compartment (e.g., the myo-endothelial space) that does not allow easy sampling. 
Theoretically, it is even possible that S-nitrosothiols are not released at all and exert their 
effects on endothelial IKCa and SKCa channels entirely through intracellular pathways. 
Finally, if B2 receptors are involved in AT2 receptor-induced vasodilation, this would 
imply that inhibitors of the EDHF pathway will also interfere with AT2 receptor-induced 
vasodilation. This should be investigated in future experiments. Confounding factors in 
this regard are the upregulation of AT2 receptors and the EDHF pathway under 
pathological conditions, the existence of AT1 receptor-AT2 receptor heterodimers, and the 
gender-related differences in the expression of components of the renin-angiotensin 
system (RAS) and the EDHF pathway. These aspects should therefore be taken into 
consideration when designing new studies.  
 
AT1 and α1-adrenergic receptor interaction 
The RAS and the sympathetic nervous system interact in several ways. Ang II increases 
the vascular sensitivity to α1-adrenoceptor agonists,146 improves central sympathetic 
outflow,157,158 and facilitates the release of catecholamines from peripheral sympathetic 
neurons via ganglionic and axonal presynaptic receptors.159,160 Vice versa, catecholamines 
stimulate renin release via renal β1-adrenoceptors.  
Our study is the first to directly demonstrate AT1-α1-receptor interaction in humans. 
The interaction may occur both at the receptor level (i.e., physical interaction through 
heterodimerization) and at the second messenger level (inositol phosphate generation). 
Future studies should delineate to what degree the enhanced second messenger generation 
is the consequence of constitutive physical association. Such studies should also verify 
the α1-adrenoreceptor subtype(s) (A, B and/or D) that contribute(s) to this phenomenon 
in HCMAs. Furthermore, other second messenger(s) that mediate the interaction should 
be considered, in particular 20-hydroxyeicosatetraeonic acid (20-HETE). Ang II 
stimulates 20-HETE production,176 and 20-HETE has been reported to increase the 
sensitivity to phenylephrine in renal interlobar arteries.177 Finally, the possibility of Ang II 
potentiation by phenylephrine should be investigated.   
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The current data explain why the non-selective β- and α1-adrenoceptor antagonist 
carvedilol antagonizes Ang II. In addition, this Ang II-antagonizing capacity offers an 
explanation for the beneficial metabolic effects of carvedilol versus metoprolol.143 RAS 
blockade prevents the onset of diabetes in hypertensive patients and reduces 
cardiovascular and renal disease progression in diabetic patients with hypertension.178-180 
Most likely, this relates to the fact that Ang II reduces insulin sensitivity.181 Alternatively, 
the antidiabetic effects might be explained on the basis of the peroxisome proliferator-
activated receptor-γ (PPARγ) activity of (some) AT1 receptor antagonists,182,183 and/or the 
bradykinin-potentiating effects of ACE inhibitors.184 Thus, to fully understand the 
metabolic effects of carvedilol on top of RAS blockade, future studies should unravel the 
respective role(s) of Ang II, bradykinin and PPARγ in this regard. 
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Introductie and doel (Hoofdstuk 1) 
Het renine-angiotensine systeem (RAS) reguleert de bloeddruk en de water- en zout 
huishouding in het lichaam. Angiotensine (Ang) II is het actieve eindproduct van het 
RAS. Ang II verhoogt de bloeddruk door binding aan Ang II type 1 (AT1) receptoren in 
de vaatwand. Verschillende studies naar de werking van Ang II type 2 (AT2) receptoren 
berichten dat de AT2 receptor dienst doet als tegenpool van de AT1 receptoren. Veel is 
hier nog niet over bekend en zeker niet in de mens.  
Het effect van vaatverwijding via de AT2 receptoren wordt gemedieerd door 
bradykinine type 2 (B2) receptoren, die vervolgens zorgen voor stimulatie van de afgifte 
van stikstofmonoxide (NO). Dit proces vindt waarschijnlijk plaats in de endotheelcellen 
van de bloedvatwand. AT2 receptoren kunnen mogelijk de afgifte van bradykinine 
stimuleren of een directe interactie met de B2 receptoren aangaan zonder dat bradykinine 
hier zelf bij betrokken is. Stimulatie van de B2 receptor resulteert naast NO afgifte ook in 
de afgifte van een groot aantal endotheliale hyperpolarizerende factoren (EDHF’s), zoals 
K+, prostacycline, waterstofperoxide and S-nitrososothiolen. Zodoende kunnen wellicht 
een aantal of alle EDHF’s bijdragen aan de vaatverwijding via de AT2 receptor. Het doel 
van dit proefschrift is om de vaatverwijding via de AT2 receptor verder te bestuderen in 
de mens en daarbij aandacht te besteden aan de identiteit van EDHF. Daarnaast is de 
interactie tussen AT1 en α1-adrenerge receptoren bestudeerd, om een verklaring te vinden 
voor de Ang II-remmende effecten van de niet-selectieve β- en α1-adrenoceptor 
antagonist carvedilol. 
 
AT2 receptoren en vasorelaxatie in de mens (Hoofdstuk 2) 
Ang II contraheert humane coronaire microarteriën (HCMA’s) door activatie van AT1 
receptoren. Pre-incubatie van HCMA segmenten met de AT2 receptor antagonist 
PD123319 verhoogde het constrictoire effect van Ang II, een fenomeen dat vooral 
aanwezig was bij oudere mensen. Dit effect verdween na verwijdering van het endotheel 
en tijdens blokkade van B2 receptoren of NO synthase (NOS).  
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Blootstelling aan Ang II van vooraf gecontraheerde HCMA’s in de aanwezigheid van 
de AT1 receptor antagonist irbesartan (zodat selectieve AT2 receptor activatie mogelijk is) 
resulteerde in relaxatie. PD123319 blokkeerde dit effect volledig. Radioligand 
bindingsstudies and RT-PCR bevestigden dat AT1 and AT2 receptoren in HCMA’s 
aanwezig zijn. Samenvattend zijn deze data de eerste die vaatverwijding via de AT2 
receptor in humane coronairen bevestigen. Dit effect is afhankelijk van endotheliale B2 
receptoren en NO, en neemt waarschijnlijk toe met de leeftijd. 
 
De identiteit van EDHF (Hoofdstukken 3, 4 en 5) 
Om verder inzicht te krijgen in de identiteit van EDHF werd door bradykinine 
geïnduceerde vaatrelaxatie bestudeerd in HCMA’s, coronaire microarteriën van varkens 
(PCMA’s) en grote coronaire arteriën van varkens (PCA’s), in de afwezigheid en 
aanwezigheid van remmers van NO en/of EDHF. 
In overeenstemming met de literatuur was tijdens de relaxatie het aandeel van door 
NOS gevormd NO belangrijker in grote arteriën dan in microarteriën. In alle vaten 
induceerde de NO scavenger hydroxocobalamin een grotere mate van remming van de 
respons op bradykinine dan de NOS remmer L-NAME. Dit suggereert dat er ook NO 
wordt afgegeven uit een andere bron dan L-arginine, bijvoorbeeld uit NO-bevattende S-
nitrosothiolen.  
In afwezigheid van NO werd de respons op bradykinine volledig geblokkeerd door 
een combinatie van remmers van intermediate- en small-conductance Ca2+-geactiveerde 
K+-kanalen (IKCa, SKCa) en door de Na+/K+-ATPase remmer ouabaïne. Ouabaïne 
verminderde ook de respons op de NO donor SNAP, terwijl gecombineerde blokkade van 
IKCa and SKCa kanalen dit niet deed. De door bradykinine geïnduceerde reacties werden 
niet beïnvloed door remmers van catalase, cyclooxygenase, cytochroom P450 
epoxygenase, gap junctions en large-conductance Ca2+-geactiveerde K+-kanalen (BKCa). 
Samengevat suggereren deze resultaten dat de door bradykinine geïnduceerde relaxatie in 
humane en varkens coronairen afhankelijk is van de activatie van guanylyl cyclase en 
Na+/K+-ATPase door NO, en van de activatie van IKCa and SKCa kanalen door een factor 
die niet de novo gevormd NO is. Aanvullende studies maakten duidelijk dat deze factor 
waarschijnlijk een S-nitrosothiol is.  
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Interactie tussen AT1 en α1-adrenerge receptoren (Hoofdstuk 6) 
Carvedilol, de selectieve β1-adrenoceptor antagonist metoprolol, de niet-selectieve β-
adrenoceptor antagonist propranolol, en de α1-adrenoceptor antagonist prazosin 
beïnvloedden geen van allen de constrictoire respons van HCMA’s op Ang II.  
Ang II, na toevoeging aan het orgaan bad in een lage (non-constrictoire) concentratie, 
versterkte de respons op de α1-adrenoceptor agonist fenylefrine enorm. Zowel carvedilol 
als de AT1 receptor antagonist irbesartan remden deze door Ang II geïnduceerde 
potentiatie. Carvedilol remde eveneens de door Ang II versterkte ophoping van 
inositolfosfaten onder invloed van fenylefrine in hartspiercellen. Samenvattend kan 
gesteld worden dat AT1-α1-receptor ‘crosstalk’, mogelijk via inositolfosfaten, HCMA’s 
gevoeliger maakt voor α1-adrenoceptor agonisten. De α1-adrenoceptor blokkerende 
effecten van carvedilol zorgen er voor dat carvedilol dit potentiërende effect van Ang II 
tegen kan gaan. Dit verklaart waarom het bloeddrukverhogende effect van Ang II bij 
patiënten met hartfalen die behandeld worden met carvedilol kleiner is dan bij patiënten 
die behandeld worden met metoprolol 
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Dankwoord 
 
Nooit gedacht dat ik zover zou komen! Natuurlijk is het onmogelijk om dit in je eentje 
voor mekaar te krijgen en daarom wil ik dit gedeelte van mijn proefschrift wijden aan 
iedereen die me hierin gesteund heeft. 
 
Als eerste wil ik mijn promotor bedanken. Jan, in de laatste vier jaar heb ik veel van je 
geleerd en je gaf me alle kans om me verder te ontwikkelen, ook je nieuwsgierigheid over 
wat er gebeurde op het lab en de tijd die je altijd voor me vrij maakte waardeer ik enorm. 
Je gaf me de gelegenheid om naar Berlijn te gaan en daar ontzettend veel nieuwe dingen 
te leren. Berlijn was een enorme uitdaging voor me en mijn tijd daar was geweldig.  
Prof. Saxena wil ik bedanken voor de altijd aanwezige intresse in mij en mijn onderzoek. 
Ik wil Prof.dr. Jos Lamers, Prof.dr. Peter de Leeuw, Prof.dr. Maarten Schalekamp en dr. 
Jacqueline Witteman bedanken voor hun bijdrage in het beoordelen van mijn proefschrift 
en het plaatsnemen in mijn commissie. Prof.dr. Michael Bader bedank ik voor zijn komst 
naar Rotterdam, erg leuk dat u na onze samenwerking in Berlijn nu aanwezig wilt zijn als 
lid van mijn promotiecommissie. 
 
Tijdens mijn sollicitatie kreeg ik een rondleiding van Martin. Toen we even stilstonden 
bij de Mulvany myographs vertelde hij me dat deze apparatuur nooit meer gebruikt werd, 
niet wetende dat uiteindelijk het grootste gedeelte van mijn proefschrift tot stand zou 
komen door middel van deze techniek. De Mulvany’s werden al snel erg gewild en al 
gauw moest ik vechten om de orgaanbadjes met Saurabh. Saurabh, thanks for the great 
time in and outside the lab and for supporting me as my paranymph. Ook René bedankt 
voor je hulp en gezelligheid op het lab en de experimenten die je voor me hebt gedaan. 
Ook heb ik met veel plezier samengewerkt met René en Jeanette van Interne 
Geneeskunde. Ik wil de Hartkleppenbank en zijn medewerkers bedanken voor de prettige 
samenwerking en het mogelijk maken van mijn experimenten in humane kransslagaders.  
Mijn kamergenoten Erik, Wenxia, Sue, Inge, Ingrid en Uday bedankt voor de gezellige 
tijd op nummer 1424. Niet te vergeten de rest uit ‘Jan’s groep’, Martin, Beril, Jasper, 
Aloys, Mark en Joep. En de rest van de (ex-)collega’s, Antoinette, Birgitte, Magda, Ria, 
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Anna, Vijay, Hari, Regien, Richard, Jan, Rémon, Andor, Roeland, Suneet, Pankaj, 
Edwin, Jailin, Wang Yong, Silvia, Thomas, Florian, Michaela en iedereen die ik vergeten 
ben.  
 
Pap en mam bedankt voor jullie steun en vertrouwen in alles wat ik deed ook al was dat 
iets verder weg dan jullie eigenlijk leuk vonden. Peter, het is zo handig dat je zoveel van 
computers af weet! Je hebt me gered in Berlijn. Dennis, ik ben heel erg blij dat je me 
bijstaat als paranimf, we hebben altijd veel lol samen en ik weet zeker dat jij, Saurabh en 
ik een goed team vormen tijdens mijn promotie.  
Ik heb er sinds kort een hele gezellige familie bij. Arie, Corrie, Sonja, Willem en de kids, 
jullie zijn altijd zo geïnteresseerd in wat ik doe en al lijkt het af en toe moeilijk te 
begrijpen, het valt allemaal wel mee! 
Lieve Marco, hoe snel kan alles gaan. Je steunt me in alles wat ik doe en hebt zoveel 
vertrouwen in me, super dat je in mijn leven bent gekomen. Ik kijk ontzettend uit naar de 
tijd samen met jou in ons eigen huisje. 
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Curriculum vitae 
 
De auteur van dit proefschrift werd geboren op 18 oktober 1976 te Sliedrecht. Nadat zij 
het VWO diploma behaalde aan de Lage Waard te Papendrecht in 1995, begon ze aan de 
opleiding Fundamentele Biomedische Wetenschappen aan de Universiteit van Utrecht om 
deze vervolgens in 2000 met het doctoraalexamen af te ronden. Tijdens de doctoraalfase 
liep zij haar eerste stage in Utrecht bij de afdeling Veterinaire Farmacie Farmacologie en 
Toxicologie. Onder leiding van prof.dr. J. Fink-Gremmels bestudeerde ze de mogelijke 
rol van haem oxygenase en xanthine oxidase bij de afbraak van cytochroom P450 in in 
vitro celsystemen. Ze vervolgde haar studie met haar tweede stage bij Programme on 
Mycotoxins and Experimental Carcinogenesis, Medical Research Council, te Kaapstad, 
Zuid-Afrika onder begeleiding van dr. W. Gelderblom. Hier was ze betrokken bij het 
bestuderen van de mogelijke anti-mutageniteit van twee inheemse theesoorten, rooibos 
(Aspalathus Linearis) en honeybush thee (Cyclopia Intermedia) en hun invloed op de 
enzymen glutathione-S-transferase en cytochroom P450. In haar afstudeerscriptie richtte 
zij zich op de drugsresistentie van patienten met hepatitis C. Sinds mei 2001 is ze 
werkzaam geweest als assistent in opleiding op de afdeling Farmacologie van het 
Erasmus MC te Rotterdam onder supervisie van prof.dr. A.H.J. Danser. Tijdens deze 
periode heeft ze een half jaar Rotterdam verruild voor Berlijn waar ze onder leiding van 
dr. D.N. Müller en prof.dr. M. Bader deelnam aan het onderzoek naar de renine receptor, 
om mogelijk via siRNA downregulatie van de receptor te bewerkstelligen. Haar 
onderzoek onder directe leiding van haar promotor prof.dr. A.H.J. Danser resulteerde in 
dit proefschrift. 
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Abbreviations 
ACE   angiotensin converting enzyme 
Ang    angiotensin 
apa   apamin 
AT1   angiotensin II type 1 
AT2   angiotensin II type 2 
B2   bradykinin type 2 
BKCa   large-conductance Ca2+-activated K+ channel 
cGMP   cyclic guanylylmonophosphate 
char   charybdotoxin 
CHF   chronic heart failure 
CRC   concentration response curve 
DEA-NONOate  dietylamine NONOate 
D-SNC   D-S-nitrosocysteine 
EDHF   endothelium-derived hyperpolarizing factor 
EET   epoxyeicosatrienoic acid 
ET-1   endothelin-1 
eYFP   enhanced yellow fluorescent protein 
HC   hydroxocobalamin 
HCA   human coronary artery 
HCMA   human coronary microartery 
HEK293  human embryonic kidney cells 293 
iber   iberiotoxin 
IKCa   intermediate-conductance Ca2+-activated K+ channel 
InsPn   inositolphospates 
KIR   inwardly rectifying K+ channel 
KV   voltage gated K+ channel 
L-NAME  Nω-nitro-L-arginine methyl ester HCl 
L-NOARG  Nω-nitro-L-arginine 
L-SNC   L-S-nitrosocysteine 
L-SNG   L-S-nitrosoglutathione 
NO   nitrix oxide 
NOS   nitrix oxide synthase 
PCA   porcine coronary artery 
PCMA   porcine coronary microartery 
PHMBA  p-hydroxymercurobezoic acid 
PE   phenylephrine 
RAS   renin angiotensin system 
RMP   resting membrane potential 
RT-PCR  reverse transcriptase polymerase chain reaction 
SKCa   small-conductance Ca2+-activated K+ channel 
SNAP   S-nitroso N-penicillamine 
TxA2   thromboxane A2 
U46619  9,11-dideoxy-11α,9α-epoxymethano-prostaglandin F2α
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